DE10331500A1 - Novel acridine derivatives and their use as pharmaceuticals - Google Patents
Novel acridine derivatives and their use as pharmaceuticals Download PDFInfo
- Publication number
- DE10331500A1 DE10331500A1 DE10331500A DE10331500A DE10331500A1 DE 10331500 A1 DE10331500 A1 DE 10331500A1 DE 10331500 A DE10331500 A DE 10331500A DE 10331500 A DE10331500 A DE 10331500A DE 10331500 A1 DE10331500 A1 DE 10331500A1
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 title claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- -1 (C 6 -C 14 ) -aryl (C 1 -C 4 ) -alkyl radical Chemical class 0.000 claims description 78
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 150000001875 compounds Chemical group 0.000 claims description 40
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 22
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 22
- 150000001251 acridines Chemical class 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- NBWVXTRXYYWHIU-UHFFFAOYSA-N (1,3-dihydroxyacridin-9-yl)-[4-(3-methoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=C(O)C=C(O)C=C3N=C3C=CC=CC3=2)=C1 NBWVXTRXYYWHIU-UHFFFAOYSA-N 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- JBRWHCOMHPRUQG-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 JBRWHCOMHPRUQG-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims description 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- OLNBGCKWUZOABX-UHFFFAOYSA-N (1,3-dihydroxyacridin-9-yl)-[4-(3-hydroxyphenyl)piperazin-1-yl]methanone Chemical compound OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=C(O)C=C(O)C=C3N=C3C=CC=CC3=2)=C1 OLNBGCKWUZOABX-UHFFFAOYSA-N 0.000 claims description 11
- SMOJQLHMZLDFQN-UHFFFAOYSA-N (1,3-dihydroxyacridin-9-yl)-[4-(6-methoxypyridin-2-yl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=C(O)C=C(O)C=C3N=C3C=CC=CC3=2)=N1 SMOJQLHMZLDFQN-UHFFFAOYSA-N 0.000 claims description 11
- FOSYFRARYPNLBE-UHFFFAOYSA-N (1,3-dihydroxyacridin-9-yl)-[4-(6-methylpyridin-2-yl)piperazin-1-yl]methanone Chemical compound CC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=C(O)C=C(O)C=C3N=C3C=CC=CC3=2)=N1 FOSYFRARYPNLBE-UHFFFAOYSA-N 0.000 claims description 11
- ZEMOGYYUIINJJG-UHFFFAOYSA-N [1-acetyloxy-9-[4-(3-methoxyphenyl)piperazine-1-carbonyl]acridin-3-yl] acetate Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=C(OC(C)=O)C=C(OC(C)=O)C=C3N=C3C=CC=CC3=2)=C1 ZEMOGYYUIINJJG-UHFFFAOYSA-N 0.000 claims description 11
- PGXKRPPYQNXWRO-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] acetate Chemical compound CC(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 PGXKRPPYQNXWRO-UHFFFAOYSA-N 0.000 claims description 11
- LDUHRKFBXPBHSP-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 LDUHRKFBXPBHSP-UHFFFAOYSA-N 0.000 claims description 11
- HYNJIYLPGNMADR-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] n-(2-hydroxyethyl)carbamate Chemical compound OCCNC(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 HYNJIYLPGNMADR-UHFFFAOYSA-N 0.000 claims description 11
- OIOZQHBBDJGWID-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(1,3-dihydroxyacridin-9-yl)methanone Chemical compound C=12C=CC=CC2=NC2=CC(O)=CC(O)=C2C=1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 OIOZQHBBDJGWID-UHFFFAOYSA-N 0.000 claims description 11
- XTSOWSRLDTUOBS-UHFFFAOYSA-N [4-(6-chloropyridin-2-yl)piperazin-1-yl]-(1,3-dihydroxyacridin-9-yl)methanone Chemical compound C=12C=CC=CC2=NC2=CC(O)=CC(O)=C2C=1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=N1 XTSOWSRLDTUOBS-UHFFFAOYSA-N 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 150000003254 radicals Chemical class 0.000 claims description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000003367 polycyclic group Chemical group 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 5
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- OOGYVVYCCYJADG-UHFFFAOYSA-N acridine-1-carboxylic acid Chemical compound C1=CC=C2C=C3C(C(=O)O)=CC=CC3=NC2=C1 OOGYVVYCCYJADG-UHFFFAOYSA-N 0.000 claims description 2
- 125000002015 acyclic group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005332 alkyl sulfoxy group Chemical group 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005469 ethylenyl group Chemical group 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000006038 hexenyl group Chemical group 0.000 claims description 2
- 125000005980 hexynyl group Chemical group 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910001437 manganese ion Inorganic materials 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims description 2
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims description 2
- 125000005981 pentynyl group Chemical group 0.000 claims description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 238000006386 neutralization reaction Methods 0.000 claims 2
- 101100495769 Caenorhabditis elegans che-1 gene Proteins 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 102000004243 Tubulin Human genes 0.000 description 9
- 108090000704 Tubulin Proteins 0.000 description 9
- RGQAEMAGSUIOFT-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] 2-chloroethyl carbonate Chemical compound ClCCOC(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 RGQAEMAGSUIOFT-UHFFFAOYSA-N 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- OKVBFNMQZWBVPQ-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 OKVBFNMQZWBVPQ-UHFFFAOYSA-N 0.000 description 8
- LNKAXVLZWMWVCI-UHFFFAOYSA-N bis[3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] carbonate Chemical compound C1=CC=C2C(C(=O)N3CCN(CC3)C=3C=CC=C(C=3)OC(OC=3C=C(C=CC=3)N3CCN(CC3)C(=O)C=3C4=CC=CC=C4N=C4C=CC=CC4=3)=O)=C(C=CC=C3)C3=NC2=C1 LNKAXVLZWMWVCI-UHFFFAOYSA-N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- JPMZWCWQWQLRMZ-UHFFFAOYSA-N C1=CC=C2C(C(=O)N3CCN(CC3)C=3C=CC=C(C=3)OP(=O)(OC=3C=C(C=CC=3)N3CCN(CC3)C(=O)C=3C4=CC=CC=C4N=C4C=CC=CC4=3)O)=C(C=CC=C3)C3=NC2=C1 Chemical compound C1=CC=C2C(C(=O)N3CCN(CC3)C=3C=CC=C(C=3)OP(=O)(OC=3C=C(C=CC=3)N3CCN(CC3)C(=O)C=3C4=CC=CC=C4N=C4C=CC=CC4=3)O)=C(C=CC=C3)C3=NC2=C1 JPMZWCWQWQLRMZ-UHFFFAOYSA-N 0.000 description 7
- ZASRWRXGNBLPCK-UHFFFAOYSA-N [3-[4-(acridine-9-carbonyl)piperazin-1-yl]phenyl] methyl carbonate Chemical compound COC(=O)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 ZASRWRXGNBLPCK-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- WHLSIRWUOSYRKP-UHFFFAOYSA-N acridin-9-yl-[4-(3-hydroxyphenyl)piperazin-1-yl]methanone Chemical compound OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 WHLSIRWUOSYRKP-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003958 fumigation Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- LRJUYAVTHIEHAI-UHFFFAOYSA-N Muristeron A Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21O LRJUYAVTHIEHAI-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- SZGUKOZBMYOFDK-UHFFFAOYSA-N acridin-1-yl(piperazin-1-yl)methanone Chemical class C=1C=CC2=NC3=CC=CC=C3C=C2C=1C(=O)N1CCNCC1 SZGUKOZBMYOFDK-UHFFFAOYSA-N 0.000 description 2
- MEQCJRDEMARLGX-UHFFFAOYSA-N acridin-9-yl-[4-[3-[bis(dimethylamino)phosphoryloxy]phenyl]piperazin-1-yl]methanone Chemical compound CN(C)P(=O)(N(C)C)OC1=CC=CC(N2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=C3C=CC=CC3=2)=C1 MEQCJRDEMARLGX-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000009448 modified atmosphere packaging Methods 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JYTNCILGSJWIDM-UHFFFAOYSA-N 1,3-dihydroxyacridine-9-carboxylic acid Chemical compound OC1=CC(O)=C2C(C(=O)O)=C(C=CC=C3)C3=NC2=C1 JYTNCILGSJWIDM-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 description 1
- AYGYICRITMSJOC-UHFFFAOYSA-N 3-piperazin-1-ylphenol Chemical compound OC1=CC=CC(N2CCNCC2)=C1 AYGYICRITMSJOC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- IYNDUQTYGRPHHW-UHFFFAOYSA-N 4-methoxy-2-nitrobenzenesulfonic acid Chemical compound COC1=CC=C(S(O)(=O)=O)C([N+]([O-])=O)=C1 IYNDUQTYGRPHHW-UHFFFAOYSA-N 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- LRJUYAVTHIEHAI-LHBNDURVSA-N Muristerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-LHBNDURVSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- ZQAZWHSZYVXGMP-UHFFFAOYSA-N acridine-9-carboxylic acid;hydrate Chemical compound O.C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=NC2=C1 ZQAZWHSZYVXGMP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SPUCQBCMTXYUBA-UHFFFAOYSA-N bis(dimethylamino)phosphinic acid hydrochloride Chemical compound Cl.CN(C)P(O)(=O)N(C)C SPUCQBCMTXYUBA-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- SRZWJXLDVCHJGO-UHFFFAOYSA-N methyl hydrogen sulfate;10-methyl-5h-phenazine Chemical compound COS(O)(=O)=O.C1=CC=C2N(C)C3=CC=CC=C3NC2=C1 SRZWJXLDVCHJGO-UHFFFAOYSA-N 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PPJWMNPSKPESFN-UHFFFAOYSA-N n-benzyl-n'-cyclohexylmethanediimine Chemical compound C=1C=CC=CC=1CN=C=NC1CCCCC1 PPJWMNPSKPESFN-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical class OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/64—Acridine or hydrogenated acridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Die Erfindung betrifft neue Acridin-Derivate der allgemeinen Formel 1, deren Herstellung und Verwendung als Arzneimittel, insbesondere zur Behandlung von Tumoren. DOLLAR F1The invention relates to novel acridine derivatives of general formula 1, their preparation and use as medicaments, in particular for the treatment of tumors. DOLLAR F1
Description
Für die nächsten Jahre wird ein dramatischer Anstieg der Tumorerkrankungen und der Tumor bedingten Todesfälle weltweit erwartet. In 2001 waren weltweit etwa 10 Mio Menschen an Krebs erkrankt und über 6 Mio Menschen sind an dieser Erkrankung gestorben. Die Entwicklung von Tumoren ist eine fundamentale Erkrankung höherer Organismen im Pflanzen-, im Tierreich und beim Menschen. Das allgemein anerkannte Mehrschrittmodell der Krebsentstehung geht davon aus, daß durch Anhäufung von mehreren Mutationen in einer einzelnen Zelle diese so in ihrem Proliferations- und Differenzierungs-verhalten geändert wird, daß letztendlich über benigne Zwischenstufen ein maligner Zustand mit Metastasierung erreicht wird. Hinter dem Begriff Krebs oder Tumor verbirgt sich ein Krankheitsbild mit mehr als 200 verschiedenen Einzelerkrankungen. Tumorerkrankungen können gutartig oder bösartig verlaufen. Die wichtigsten Tumoren sind die der Lunge, der Brust, des Magens, des Gebärmutterhalses, der Prostata, des Kopfes und Halses, des Dick- und Enddarmes, der Leber und des Blutsystems. Hinsichtlich Verlauf, Prognose und Therapieverhalten gibt es große Unterschiede. Mehr als 90% der erkannten Fälle betreffen solide Tumoren, die insbesondere in fortgeschrittenem Stadium bzw. bei Metastasierung schwer oder nicht therapierbar sind. Die drei Säulen der Krebsbekämpfung sind nach wie vor operative Entfernung, Bestrahlung und Chemotherapie. Trotz großer Fortschritte ist es bisher nicht gelungen, Medikamente zu entwickeln, die bei den weitverbreiteten soliden Tumoren eine deutliche Verlängerung der Überlebenszeit oder gar komplette Heilung bewirken. Es ist deshalb sinnvoll, neue Arzneimittel zur Bekämpfung der Krebserkrankung zu erfinden.For the next years will be a dramatic increase in the tumors and the tumor conditional deaths expected worldwide. In 2001 there were about 10 million people worldwide Cancer is ill and over 6 million people died of this disease. The development of tumors is a fundamental disease of higher organisms in plant, in the animal kingdom and in humans. The generally accepted multi-step model Carcinogenesis assumes that by accumulating multiple mutations in a single cell, they are thus in their proliferation and differentiation behavior changed that will ultimately be about benign Intermediates reached a malignant condition with metastasis becomes. The term cancer or tumor hides a clinical picture with more than 200 different single diseases. tumor diseases can benign or vicious run. The most important tumors are those of the lungs, the chest, of the stomach, cervix, prostate, head and neck, colon and rectum, liver and blood system. With regard to course, prognosis and therapy behavior, there are great differences. More than 90% of detected cases involve solid tumors, especially in advanced stages or are difficult or impossible to treat in metastasis. The three columns fighting cancer still surgical removal, radiation and chemo. Despite big Advances have so far failed to develop drugs which in the widespread solid tumors a significant extension the survival time or even cause complete healing. It makes sense, therefore, new Medicines to combat to invent cancer.
Die vorliegende Erfindung betrifft neue Acridin-Derivate, deren Herstellung und Verwendung als Arzneimittel, insbesondere zur Behandlung von gutartigen und bösartigen Tumoren am Menschen und Säugetier.The The present invention relates to novel acridine derivatives, their preparation and use as a medicament, in particular for the treatment of benign and malignant Tumors on humans and mammals.
Es
wurde jetzt überraschend
gefunden, daß diese
neuen Verbindungen aus der Reihe der Aryl- und Heteroaryl-substituierten
Piperazinylcarbonyl-Acridine und deren Homologe zur Herstellung
von Arzneimitteln und diese insbesondere zur Behandlung von gutartigen
und bösartigen
Tumoren geeignet sind und die erfindungsgemäßen Verbindungen sich durch
verbesserte Wasserlöslichkeiten
gegenüber
den in der Patentschrift WO 0208194 beschriebenen Verbindungen auszeichnen.
Gemäß diesem
Aspekt werden in der vorliegenden Anmeldung neue Verbindungen aus
der Reihe der Aryl- und Heteroaryl-substituierten Piperazinylcarbonyl-acridine
gemäß der allgemeinen
Formel 1 beschrieben, worin an den C-Atomen C1-C9 des Ringgerüstes gebunden
sein kann;
Z: Sauerstoff oder Schwefel ist;
n, m: unabhängig voneinander
eine ganze Zahl zwischen 0 und 4 bedeuten;
R, R1, R2, R3: wahlweise
an die heteroaromatischen Kohlenstoffatome C1 bis
C9 des Acridins gebunden sein können, gleich
oder verschieden sind und unabhängig
voneinander: Wasserstoff, Hydroxy und OR5 bedeuten, jedoch die Reste
R, R1, R2 und R3 nicht gleichzeitig Wasserstoff bedeuten dürfen,
R4:
einen (C6-C14)-Aryl-Rest,
(C6-C14)-Aryl-(C1-C4)-alkyl-Rest
oder einen ein oder mehrere Heteroatome ausgewählt aus der Gruppe N, O und
S enthaltenden (C2-C10)-Heteroaryl-
oder (C2-C10)-Heteroaryl-(C1-C4)-alkyl-Rest, wobei
der (C1-C4)-alkyl-Rest
unsubstituiert oder ein- oder mehrfach gleich oder verschieden mit (C1-C6)-Alkyl oder
Halogen substituiert sein kann und der (C6-C14)-Aryl- oder (C2-C10)-Heteroaryl-Rest unsubstituiert oder ein- oder mehrfach
gleich oder verschieden mit geradkettigem oder verzweigtem (C1-C8)-Alkyl, (C3-C12)-Cycloalkyl,
geradkettigem oder verzweigtem (C1-C8)-Alkylcarbonyl, Hydroxy, geradkettigem
oder verzweigtem (C1-C8)-Alkoxy,
OR5, Halogen, geradkettigem oder verzweigtem Aryl-(C1-C8)-alkoxy, Trityloxy, Trimethylsilyloxy,
Amino, Mono-(C1-C4)-alkylamino,
Di-(C1-C4)-alkylamino, (C2-C5)cycloalkylamino,
Morpholino, Heterocyclyl-(C1-C6)-alkoxy, Carboxy,
Imidocarboxy, Carboxamidin, geradkettigem oder verzweigtem (C1-C8)-Alkoxycarbonylamino,
geradkettigem oder verzweigtem (C1-C8)-Alkylcarbonylamino, Sulfonyloxy, Sulfenyloxy,
Sulfinyloxo, Nitro, Nitroso, Thio, geradkettigem oder verzweigtem
(C1-C8)-Alkylthio, geradkettigem oder verzweigtem
(C1-C8)-Alkylsulfo,
geradkettigem oder verzweigtem (C1-C8)-Alkylsulfoxy, Cyano, Isocyano, geradkettigem
oder verzweigtem Cyano-(C1-C6)-alkyl,
geradkettigem oder verzweigtem (C1-C8)-Alkoxycarbonyl, mit einem oder mehreren
Halogenatomen substituiertem, geradkettigem oder verzweigtem (C1-C4)-Alkyl, geradkettigem oder verzweigtem
Carboxy-(C1-C8)-alkyl,
geradkettigem oder verzweigtem (C1-C8)-Alkoxycarbonyl-(C1-C6)-alkyl, (C2-C6)-Alkenyl, (C2-C6)-Alkinyl substituiert sein kann, bedeutet,
oder
für den
Fall, dass R, R1, R2, R3 wahlweise an die heteroaromatischen Kohlenstoffatome
C1 bis C9 des Acridins
gebunden sein können,
gleich oder verschieden sind und unabhängig voneinander:
Wasserstoff,
geradkettiges oder verzweigtes (C1-C8)-Alkyl, (C3-C7)-Cycloalky,
geradkettiges oder verzweigtes (C1-C8)-Alkylcarbonyl, Hydroxy, geradkettiges
oder verzweigtes (C1-C8)-Alkoxy,
Halogen, geradkettiges oder verzweigtes Aryl-(C1-C8)-alkoxy, Trityloxy, Trimethylsilyloxy,
Amino, Mono-(C1-C4)-alkylamino,
Di-(C1-C4)-alkylamino, (C2-C5)cycloalkylamino,
Morpholino, Heterocyclyl-(C1-C6)-alkoxy, Carboxy,
Imidocarboxy, Carboxamidin, geradkettiges oder verzweigtes (C1-C8)-Alkoxycarbonylamino,
geradkettiges oder verzweigtes (C1-C8)-Alkylcarbonylamino, Sulfonyloxy, Sulfenyloxy,
Sulfinyloxo, Nitro, Nitroso, Thio, geradkettiges oder verzweigtes (C1-C8)-Alkylthio, geradkettiges oder verzweigtes
(C1-C8)-Alkylsulfo,
geradkettiges oder verzweigtes (C1-C8)-Alkylsulfoxy, Cyano, Isocyano, geradkettiges
oder verzweigtes Cyano-(C1-C6)-alkyl,
geradkettiges oder verzweigtes (C1-C8)-Alkoxycarbonyl, mit einem oder mehreren
Halogenatomen substituiertes, geradkettiges oder verzweigtes (C1-C4)-Alkyl, geradkettiges
oder verzweigtes Carboxy-(C1-C8)-alkyl,
geradkettiges oder verzweigtes (C1-C8)-Alkoxycarbonyl-(C1-C6)-alkyl, (C2-C6)-Alkenyl, (C2-C6)-Alkinyl, Aryl, wobei der Arylrest unsubstituiert
oder ein- oder mehrfach gleich oder verschieden mit Halogen, geradkettigem
oder verzweigtem (C1-C8)-Alkyl,
(C3-C12)-Cycloalkyl,
geradkettigem oder verzweigtem (C1-C8)-Alkylcarbonyl, Hydroxy, geradkettigem
oder verzweigtem (C1-C8)-Alkoxy,
Amino, Mono-(C1-C4)-alkylamino, Di-(C1-C4)-alkylamino,
(C2-C5)cycloalkylamino,
Morpholino, Heterocyclyl-(C1-C6)-alkoxy,
Carboxy, Imidocarboxy, Carboxamidin, geradkettigem oder verzweigtem
(C1-C8)-Alkoxycarbonylamino,
geradkettigem oder verzweigtem (C1-C8)-Alkylcarbonylamino, Sulfonyloxy, Sulfenyloxy,
Sulfinyloxo, Nitro, Nitroso, Thio, geradkettigem oder verzweigtem
(C1-C8)-Alkylthio,
Cyano, Isocyano, geradkettigem oder verzweigtem (C1-C8)-Alkoxycarbonyl, mit einem oder mehreren Halogenatomen
substituiertem, geradkettigem oder verzweigtem (C1-C4)-Alkyl, (C2-C6)-Alkenyl, (C2-C6)-Alkinyl, substituiert sein kann, bedeuten,
bedeutet
R4: einen (C6-C14)-Aryl-Rest,
(C6-C14)-Aryl-(C1-C4)-alkyl-Rest
oder einen ein oder mehrere Heteroatome ausgewählt aus der Gruppe N, O und
S enthaltenden (C2-C10)-Heteroaryl-
oder (C2-C10)-Heteroaryl-(C1-C4)-alkyl-Rest, wobei
der (C1-C4)-alkyl-Rest
unsubstituiert oder ein- oder mehrfach gleich oder verschieden mit
(C1-C6)-Alkyl oder
Halogen substituiert sein kann und der (C6-C14)-Aryl- oder (C2-C10)-Heteroaryl-Rest ein- oder mehrfach gleich oder
verschieden mit OR5 substituiert sein kann,
und R5 in allen
Fällen
stehen kann für:
- – ein Sulfon der Formel -SO2-X1, wobei X1 NMe2, Hydroxyl, O-Alkyl, unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Aryl, unsubstituiertes oder substituiertes Heteroaryl, unsubstituiertes oder substituiertes Alkyl-Cycloalkyl, unsubstituiertes oder substituiertes Alkyl-Heterocyclyl, unsubstituiertes oder substituiertes Alkylaryl, unsubstituiertes oder substituiertes Alkylheteroaryl bedeuten;
- – C(O)-X2, wobei X2 unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Heterocyclyl, unsubstituiertes oder substituiertes Aryl, unsubstituiertes oder substituiertes Heteroaryl, unsubstituiertes oder substituiertes Alkyl-Cycloalkyl, unsubstituiertes oder substituiertes Alkyl-Heterocyclyl, unsubstituiertes oder substituiertes Alkylaryl und unsubstituiertes oder substituiertes Alkylheteroaryl bedeuten,
- – C(O)O-X3, wobei X3 unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Heterocyclyl, unsubstituiertes oder substituiertes Aryl, unsubstituiertes oder substituiertes Heteroaryl, unsubstituiertes oder substituiertes Alkyl-Cycloalkyl, unsubstituiertes oder substituiertes Alkyl-Heterocyclyl, unsubstituiertes oder substituiertes Alkylaryl und unsubstituiertes oder substituiertes Alkylheteroaryl bedeuten,
- – C(O)NX4X5, wobei X4 und X5 unabhängig voneinander Wasserstoff, unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Heterocyclyl, unsubstituiertes oder substituiertes Aryl, unsubstituiertes oder substituiertes Heteroaryl, unsubstituiertes oder substituiertes Alkyl-Cycloalkyl, unsubstituiertes oder substituiertes Alkyl-Heterocyclyl, unsubstituiertes oder substituiertes Alkylaryl, unsubstituiertes oder substituiertes Alkylheteroaryl bedeuten, oder X4 und X5 gemeinsam Cycloalkyl oder Cycloheteroalkyl bedeuten,
- – P(O)OX6OX7, wobei X6 und X7 unabhängig voneinander Wasserstoff, Metall, unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Heterocyclyl, unsubstituiertes oder substituiertes Aryl, unsubstituiertes oder substituiertes Heteroaryl, unsubstituiertes oder substituiertes Alkyl-Cycloalkyl, unsubstituiertes oder substituiertes Alkyl-Heterocyclyl, unsubstituiertes oder substituiertes Alkylaryl, unsubstituiertes oder substituiertes Alkylheteroaryl bedeuten, oder X6 und X7 gemeinsam Cycloalkyl oder Cycloheteroalkyl bedeuten,
- – P(O)NX8X9NX10X11, wobei X8, X9, X10 und X11 unabhängig voneinander Wasserstoff, unsubstituiertes oder substituiertes Alkyl, unsubstituiertes oder substituiertes Cycloalkyl, unsubstituiertes oder substituiertes Heterocyclyl, unsubstituiertes oder substituiertes Aryl, unsubstituiertes oder substituiertes Heteroaryl, unsubstituiertes oder substituiertes Alkyl-Cycloalkyl, unsubstituiertes oder substituiertes Alkyl-Heterocyclyl, unsubstituiertes oder substituiertes Alkylaryl, unsubstituiertes oder substituiertes Alkylheteroaryl bedeuten, oder X8 und X9 oder X10 und X11 gemeinsam Cycloalkyl oder Cycloheteroalkyl bedeuten,
- – Cycloalkyl, Alkyl-Cycloalkyl, Cycloheteroalkyl oder Alkyl-Cycloheteroalkyl bedeuten.
Z is oxygen or sulfur;
n, m: independently of one another denote an integer between 0 and 4;
R, R 1, R 2, R 3: may optionally be bonded to the heteroaromatic carbon atoms C 1 to C 9 of the acridine, are identical or different and independently of one another: hydrogen, hydroxy and OR 5, but not the radicals R, R 1, R 2 and R 3 may mean hydrogen at the same time,
R4: a (C 6 -C 14 ) -aryl radical, (C 6 -C 14 ) -aryl (C 1 -C 4 ) -alkyl radical or one or more heteroatoms selected from the group consisting of N, O and S (C 2 -C 10 ) -Heteroaryl- or (C 2 -C 10 ) -Heteroaryl- (C 1 -C 4 ) -alkyl radical, wherein the (C 1 -C 4 ) -alkyl radical is unsubstituted or mono- or polysubstituted by identical or different substituents with (C 1 -C 6 ) -alkyl or halogen and the (C 6 -C 14 ) -aryl or (C 2 -C 10 ) -heteroaryl radical unsubs substituted or mono- or polysubstituted or polysubstituted or differently with straight-chain or branched (C 1 -C 8 ) -alkyl, (C 3 -C 12 ) -cycloalkyl, straight-chain or branched (C 1 -C 8 ) -alkylcarbonyl, hydroxyl, straight-chain or branched (C 1 -C 8 ) -alkoxy, OR 5, halogen, straight-chain or branched aryl- (C 1 -C 8 ) -alkoxy, trityloxy, trimethylsilyloxy, amino, mono- (C 1 -C 4 ) -alkylamino, di-, (C 1 -C 4 ) -alkylamino, (C 2 -C 5 ) -cycloalkylamino, morpholino, heterocyclyl- (C 1 -C 6 ) -alkoxy, carboxy, imidocarboxy, carboxamidine, straight-chain or branched (C 1 -C 8 ) - Alkoxycarbonylamino, straight-chain or branched (C 1 -C 8 ) -alkylcarbonylamino, sulphonyloxy, sulfenyloxy, sulfinyloxo, nitro, nitroso, thio, straight-chain or branched (C 1 -C 8 ) -alkylthio, straight-chain or branched (C 1 -C 8 ) Alkylsulfo, straight-chain or branched (C 1 -C 8 ) -alkylsulfoxy, cyano, isocyano, straight-chain or branched cyano (C 1 -C 6 ) -alkyl, straight-chain or branched (C 1 -C 8 ) -alk oxycarbonyl, straight-chain or branched (C 1 -C 4 ) -alkyl which is substituted by one or more halogen atoms, straight-chain or branched carboxy (C 1 -C 8 ) -alkyl, straight-chain or branched (C 1 -C 8 ) -alkoxycarbonyl (C 1 -C 6 ) -alkyl, (C 2 -C 6 ) -alkenyl, (C 2 -C 6 ) -alkynyl may be substituted,
or in the event that R, R 1, R 2, R 3 can be optionally bonded to the heteroaromatic carbon atoms C 1 to C 9 of the acridine, are identical or different and independently of one another:
Hydrogen, straight-chain or branched (C 1 -C 8 ) -alkyl, (C 3 -C 7 ) -cycloalky, straight-chain or branched (C 1 -C 8 ) -alkylcarbonyl, hydroxyl, straight-chain or branched (C 1 -C 8 ) Alkoxy, halogen, straight-chain or branched aryl- (C 1 -C 8 ) -alkoxy, trityloxy, trimethylsilyloxy, amino, mono- (C 1 -C 4 ) -alkylamino, di- (C 1 -C 4 ) -alkylamino, (C 2 -C 5 ) cycloalkylamino, morpholino, heterocyclyl (C 1 -C 6 ) alkoxy, carboxy, imidocarboxy, carboxamidine, straight-chain or branched (C 1 -C 8 ) -alkoxycarbonylamino, straight-chain or branched (C 1 -C 8 ) -alkylcarbonylamino, sulphonyloxy, sulfenyloxy, sulfinyloxo, nitro, nitroso, thio, straight-chain or branched (C 1 -C 8 ) -alkylthio, straight-chain or branched (C 1 -C 8 ) -alkylsulfo, straight-chain or branched (C 1 - C 8 ) alkylsulfoxy, cyano, isocyano, straight-chain or branched cyano (C 1 -C 6 ) -alkyl, straight-chain or branched (C 1 -C 8 ) -alkoxycarbonyl, having one or more halogen atoms subs substituted, straight-chain or branched (C 1 -C 4 ) -alkyl, straight-chain or branched carboxy (C 1 -C 8 ) -alkyl, straight-chain or branched (C 1 -C 8 ) -alkoxycarbonyl- (C 1 -C 6 ) -alkyl, (C 2 -C 6 ) -alkenyl, (C 2 -C 6 ) -alkynyl, aryl, where the aryl radical is unsubstituted or monosubstituted or polysubstituted or differently identical or different with halogen, straight-chain or branched (C 1 -C 8 ) Alkyl, (C 3 -C 12 ) -cycloalkyl, straight-chain or branched (C 1 -C 8 ) -alkylcarbonyl, hydroxy, straight-chain or branched (C 1 -C 8 ) -alkoxy, amino, mono (C 1 -C 4 ) -alkylamino, di- (C 1 -C 4 ) -alkylamino, (C 2 -C 5 ) -cycloalkylamino, morpholino, heterocyclyl- (C 1 -C 6 ) -alkoxy, carboxy, imidocarboxy, carboxamidine, straight-chain or branched ( C 1 -C 8 ) -alkoxycarbonylamino, straight-chain or branched (C 1 -C 8 ) -alkylcarbonylamino, sulphonyloxy, sulfenyloxy, sulfinyloxo, nitro, nitroso, thio, straight-chain or branched (C 1 -C 8 ) -alkylthio, cyano, isocyano , straight-chain or branched (C 1 -C 8 ) -alkoxycarbonyl, (C 1 -C 4 ) -alkyl, (C 2 -C 6 ) -alkenyl, (C 2 -C 6 ) -alkynyl substituted with one or more halogen atoms, straight or branched chain , mean
R4 denotes a (C 6 -C 14 ) -aryl radical, (C 6 -C 14 ) -aryl (C 1 -C 4 ) -alkyl radical or one or more heteroatoms selected from the group N, O and S (C 2 -C 10 ) heteroaryl or (C 2 -C 10 ) heteroaryl (C 1 -C 4 ) alkyl, wherein the (C 1 -C 4 ) alkyl radical is unsubstituted or mono- or polysubstituted by identical or different substituents with (C 1 -C 6 ) -alkyl or halogen and the (C 6 -C 14 ) -aryl or (C 2 -C 10 ) -Heteroaryl radical one or may be the same or different than OR5 several times,
and R5 in all cases can stand for:
- A sulfone of the formula -SO 2 -X 1 , where X 1 is NMe 2 , hydroxyl, O-alkyl, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted substituted alkyl-heterocyclyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkylheteroaryl;
- - C (O) -X2, where X2 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted alkylheterocyclyl, unsubstituted or substituted alkylaryl and unsubstituted or substituted alkylheteroaryl,
- C (O) O-X3, where X3 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted alkylheterocyclyl, unsubstituted or substituted alkylaryl and unsubstituted or substituted alkylheteroaryl,
- - C (O) NX4X5, wherein X4 and X5 are independently hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted Alkyl heterocyclyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroaryl, or X4 and X5 ge mean cycloalkyl or cycloheteroalkyl,
- - P (O) OX6OX7, wherein X6 and X7 independently of one another are hydrogen, metal, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted alkyl heterocyclyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroaryl, or X 6 and X 7 together denote cycloalkyl or cycloheteroalkyl,
- - P (O) NX8X9NX10X11 wherein X8, X9, X10 and X11 are independently hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted alkylcycloalkyl , unsubstituted or substituted alkyl heterocyclyl, unsubstituted or substituted alkylaryl, unsubstituted or substituted alkyl heteroaryl, or X 8 and X 9 or X 10 and X 11 together denote cycloalkyl or cycloheteroalkyl,
- - Cycloalkyl, alkyl-cycloalkyl, cycloheteroalkyl or alkyl-cycloheteroalkyl mean.
Der Ausdruck „Metall" umfasst im Sinne dieser Erfindung Metallionen wie Natrium-, Kalium-, Lithium-, Magnesium-, Calcium-, Zink- und Mangan-Ionen.Of the Expression "metal" includes the meaning of this invention metal ions such as sodium, potassium, lithium, magnesium, Calcium, zinc and manganese ions.
Der Ausdruck „Alkyl" umfasst im Sinne dieser Erfindung acyclische gesättigte oder ungesättigte Kohlenwasserstoffreste, die verzweigt oder geradkettig sowie unsubstituiert oder ein- oder mehrfach substituiert sein können, mit 1 bis 20 C-Atomen, d.h. C1-20-Alkanyle, C2-20-Alkenyle und C2-20-Alkinyle. Dabei weisen Alkenyle mindestens eine C-C-Doppelbindung und Alkinyle mindestens eine C-C-Dreifachbindung auf. Vorteilhaft ist Alkyl aus der Gruppe ausgewählt, die Methyl, Ethyl, n-Propyl, 2-Propyl, n-Butyl, sec.-Butyl, tert.-Butyl, n-Pentyl, iso-Pentyl, neo-Pentyl, n-Hexyl, 2-Hexyl, n-Octyl, Ethylenyl (Vinyl), Ethinyl, Propenyl (-CH2CH=CH2; -CH=CH-CH3, -C(=CH2)-CH3), Propinyl (-CH2-C≡CH, -C≡C-CH3), Butenyl, Butinyl, Pentenyl, Pentinyl, Hexenyl, Hexinyl, Octenyl und Octinyl umfasst.Within the meaning of the term "alkyl" includes acyclic saturated or unsaturated hydrocarbon radicals which may be branched or straight chained and unsubstituted or may be mono- or polysubstituted, having 1 to 20 carbon atoms, ie C 1 - 20 -Alkanyle, C 2 - 20 alkenyls, and C 2 -.. 20 alkynyls case have alkenyls at least one C-C double bond and alkynyls one C-C triple bond Advantageously, at least alkyl selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n, Butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl, n-octyl, ethylenyl (vinyl), ethynyl, propenyl (-CH 2 CH = CH 2 ; -CH = CH-CH 3 , -C (= CH 2 ) -CH 3 ), propynyl (-CH 2 -C≡CH, -C≡C-CH 3 ), butenyl, butynyl, pentenyl, pentynyl , Hexenyl, hexynyl, octenyl and octynyl.
Der Ausdruck „Cycloalkyl" bedeutet für die Zwecke dieser Erfindung cyclische Kohlenwasserstoffe mit 3–12 Kohlenwasserstoffen, die gesättigt oder ungesättigt, unsubstituiert oder substituiert sein können. Der Cycloalkyl-Rest kann auch Teil eines bi- oder polycyclischen Systems sein.Of the Expression "cycloalkyl" means for the purposes of this invention cyclic hydrocarbons with 3-12 hydrocarbons, the saturated or unsaturated, may be unsubstituted or substituted. The cycloalkyl radical may also be part of a bi- or polycyclic system.
Der Ausdruck „Heterocyclyl" steht für einen 3-, 4-, 5-, 6-, 7- oder 8-gliedrigen cyclischen organischen Rest, der mindestens 1, ggf. 2, 3, 4 oder 5 Heteroatome enthält, wobei die Heteroatome gleich oder verschieden sind und der cyclische Rest gesättigt oder ungesättigt, aber nicht aromatisch ist und unsubstituiert oder ein- oder mehrfach substituiert sein kann. Der Heterocyclus kann auch Teil eines bi- oder polycyclischen Systems sein. Bevorzugte Heteroatome sind Stickstoff, Sauerstoff und Schwefel. Es ist bevorzugt, dass der Heterocyclyl-Rest ausgewählt ist aus der Gruppe, die Tetrahydrofuryl, Tetrahydropyranyl, Pyrrolidinyl, Piperidinyl, Piperazinyl und Morpholinyl enthält, wobei die Bindung an die Verbindung der allgemeinen Formel 1 über jedes beliebige Ringglied des Heterocyclyl-restes erfolgen kann.Of the Term "heterocyclyl" means one 3-, 4-, 5-, 6-, 7- or 8-membered cyclic organic radical, containing at least 1, optionally 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are the same or different and the cyclic radical is saturated or unsaturated, but is not aromatic and unsubstituted or one or more times may be substituted. The heterocycle may also be part of a bi- or polycyclic system. Preferred heteroatoms are nitrogen, Oxygen and sulfur. It is preferred that the heterocyclyl radical selected is from the group consisting of tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, Piperidinyl, piperazinyl and morpholinyl, wherein the binding to the Compound of general formula 1 via any ring member of the heterocyclyl radical can take place.
Der Ausdruck „Aryl" bedeutet im Sinne dieser Erfindung aromatische Kohlenwasserstoffe, u.a. Phenyle, Naphthyle und Anthracenyle. Die Reste können auch mit weiteren gesättigten, (partiell) ungesättigten oder aromatischen Ringsystemen kondensiert sein. Jeder Aryl-Rest kann unsubstituiert oder einfach oder mehrfach substituiert vorliegen, wobei die Aryl-Substituenten gleich oder verschieden und in jeder beliebigen und möglichen Position des Aryls sein können.Of the Expression "aryl" means in the sense aromatic hydrocarbons of this invention, i.a. Phenyle, naphthyls and anthracenyls. The remains can also with other saturated, (partially) unsaturated or aromatic ring systems. Every aryl residue can be unsubstituted or monosubstituted or polysubstituted, wherein the aryl substituents are the same or different and in each arbitrary and possible Position of the aryl can be.
Der Ausdruck „ Heteroaryl" steht für einen 5-, 6- oder 7-gliedrigen cyclischen aromatischen Rest, der mindestens 1, ggf. auch 2, 3, 4 oder 5 Heteroatome enthält, wobei die Heteroatome gleich oder verschieden sind und der Heterocyclus unsubstituiert oder ein- oder mehrfach substituiert sein kann; im Falle der Substitution am Heterocyclus können die Heteroarylsubstituenten gleich oder verschieden sein und in jeder beliebigen und möglichen Position des Heteroaryls sein. Der Heterocyclus kann auch Teil eines bi- oder polycyclischen Systems sein. Bevorzugte Heteroatome sind Stickstoff, Sauerstoff und Schwefel. Es ist bevorzugt, dass der Heteroaryl-Rest ausgewählt ist aus der Gruppe, die Pyrrolyl, Furyl, Thienyl, Thiazolyl, Triazolyl, Tetrazolyl, Oxazolyl, Isothiazolyl, Isoxazolyl, Pyrazolyl, Imidazolyl, Pyridinyl, Pyrimidinyl, Pyrazinyl, Triazinyl, Benzthiazolyl, Indolyl, Indolizinyl, Chinolinyl, Isochinolinyl, Cinnolinyl, Chinazolinyl, Chinoxalinyl, Phthalazinyl, Carbazolyl, Phenazinyl, Phenothiazinyl, Purinyl, Acridinyl, Phenanthrinyl, enthält, wobei die Bindung an die Verbindungen der allgemeinen Formel 1 über jedes beliebige und mögliche Ringglied des Heteroaryl-Restes erfolgen kann.Of the Expression "heteroaryl" stands for one 5-, 6- or 7-membered cyclic aromatic radical which is at least 1, optionally also contains 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are the same or are different and the heterocycle is unsubstituted or or may be substituted several times; in the case of substitution at the heterocycle the heteroaryl substituents are the same or different and in any and possible Be position of the heteroaryl. The heterocycle can also be part of a bi- or polycyclic system. Preferred heteroatoms are Nitrogen, oxygen and sulfur. It is preferred that the heteroaryl radical selected is from the group comprising pyrrolyl, furyl, thienyl, thiazolyl, triazolyl, Tetrazolyl, oxazolyl, isothiazolyl, isoxazolyl, pyrazolyl, imidazolyl, Pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, benzthiazolyl, indolyl, Indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, Quinoxalinyl, phthalazinyl, carbazolyl, phenazinyl, phenothiazinyl, Purinyl, acridinyl, phenanthrinyl, wherein the binding to the Compounds of general formula 1 via any and possible ring member of the heteroaryl radical can take place.
Die Ausdrücke „Alkyl-Cycloalkyl", „Alkyl-Heterocyclyl", „Alkyl-Aryl" oder „Alkyl-Heteroaryl" bedeuten für die Zwecke der vorliegenden Erfindung, dass Alkyl und Cycloalkyl, Heterocyclyl, Aryl und Heteroaryl die oben definierten Bedeutungen haben und der Cycloalkyl-, Heterocyclyl-, Aryl- bzw. Heteroaryl-Rest über eine C1-8-Alkyl-Gruppe an die Verbindung der allgemeinen Formel 1 gebunden ist.The terms "alkyl-cycloalkyl", "alkyl-heterocyclyl", "alkyl-aryl" or "alkyl-heteroaryl" mean for the purposes of the present invention that alkyl and cycloalkyl, heterocyclyl, aryl and heteroaryl are as above have defined meanings and the cycloalkyl, heterocyclyl, aryl or heteroaryl radical is bonded via a C 1-8 -alkyl group to the compound of the general formula 1.
Im Zusammenhang mit „Alkyl", „Alkenyl" und „Alkinyl" versteht man unter dem Begriff substituiert im Sinne dieser Erfindung die Substitution eines Wasserstoffrestes durch F, Cl, Br, I, CN, NH2, NH-Alkyl, NH-Cycloalkyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, NH-Heterocyclyl, NH-Alkyl-OH, N(Alkyl)2, N(Alkyl-Aryl)2, N(Alkyl-Heteroaryl)2, N(Heterocyclyl)2, N(Alkyl-OH)2, NO, NO2, SH, S-Alkyl, S-Cycloalkyl, S-Aryl, S-Heteroaryl, S-Alkyl-Aryl, S-Alkyl-Heteroaryl, S-Heterocyclyl, S-Alkyl-OH, S-Alkyl-SH, S-Alkyl, S-S-Cycloalkyl, S-S-Aryl, S-S-Heteroaryl, S-S-Alkyl-Aryl, S-S-Alkyl-Heteroaryl, S-S-Heterocyclyl, S-S-Alkyl-OH, S-S-Alkyl-SH, S-S-Alkyl-C(O)-NH-Heterocyclyl, OH, O-Alkyl, O-Cycloalkyl, O-Aryl, O-Heteroaryl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, O-Heterocyclyl, O-Alkyl-OH, CHO, C(O)-Alkyl, C(S)-Alkyl, C(O)-Aryl, C(S)-Aryl, C(O)-Alkyl-Aryl, C(S)-Alkyl-Aryl, C(O)-Heterocyclyl, C(O)-Heteroaryl, C(O)-Alkyl-Heteroaryl, C(S)-Heterocyclyl, CO2H, CO2-Alkyl, CO2-Cyclyl, CO2-Heterocyclyl, CO2-Aryl, CO2-Heteroaryl, CO2-Alkyl-Aryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-Aryl, C(O)NH-Heterocyclyl, C(O)NH-Alkyl-Heterocyclyl, C(O)N(Alkyl)2, C(O)N(Alkyl-Aryl)2, C(O)N(Alkyl-Heteroaryl)2, C(O)N(Heterocyclyl)2, SO-Alkyl, SO2-Alkyl, SO2NH2, SO3H, Alkyl, Cycloalkyl, Aryl, Heteroaryl, oder Heterocyclyl, wobei unter mehrfach substituierten Resten solche zu verstehen sind, die entweder an verschiedenen oder an gleichen Atomen mehrfach, z.B. zwei- oder dreifach substituiert sind, beispielsweise dreifach am gleichen C-Atom wie im Falle von CF3, -CH2CF3 oder an verschiedenen Stellen wie im Falle von -CH(OH)-CH=CH-CHC12. Die Mehrfachsubstitution kann mit dem gleichen oder verschiedenen Substituenten erfolgen.In the context of "alkyl", "alkenyl" and "alkynyl", the term "substituted" in the context of this invention means the substitution of a hydrogen radical by F, Cl, Br, I, CN, NH 2 , NH-alkyl, NH-cycloalkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, N (alkyl) 2 , N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl-OH) 2 , NO, NO 2 , SH, S-alkyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-alkyl-aryl, S-alkyl-heteroaryl , S-heterocyclyl, S-alkyl-OH, S-alkyl-SH, S-alkyl, SS-cycloalkyl, SS-aryl, SS-heteroaryl, SS-alkyl-aryl, SS-alkyl-heteroaryl, SS-heterocyclyl, SS -Alkyl-OH, SS-alkyl-SH, SS-alkyl-C (O) -NH-heterocyclyl, OH, O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O- Alkyl heteroaryl, O-heterocyclyl, O-alkyl-OH, CHO, C (O) -alkyl, C (S) -alkyl, C (O) -aryl, C (S) -aryl, C (O) -alkyl -Aryl, C (S) -alkyl-aryl, C (O) -heterocyclyl, C (O) -heteroaryl, C (O) -alkyl-heteroaryl, C (S) -heterocyclyl, CO 2 H, CO 2 -alkyl , CO 2 - Cyclyl, CO 2 -heterocyclyl, CO 2 -aryl, CO 2 -heteroaryl, CO 2 -alkyl-aryl, C (O) -NH 2 , C (O) -NH-alkyl, C (O) -NH-aryl, C ( O) NH-heterocyclyl, C (O) NH-alkyl-heterocyclyl, C (O) N (alkyl) 2 , C (O) N (alkyl-aryl) 2 , C (O) N (alkyl-heteroaryl) 2 , C (O) N (heterocyclyl) 2 , SO-alkyl, SO 2 alkyl, SO 2 NH 2 , SO 3 H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, where poly-substituted radicals are to be understood as meaning those are either multiply substituted on different or on the same atoms, for example two or three times, for example three times on the same C atom as in the case of CF 3 , -CH 2 CF 3 or at different positions as in the case of -CH (OH) - CH = CH-CHCl 2 . The multiple substitution can be with the same or different substituent.
In Bezug auf Aryl, Heterocyclyl, Heteroaryl, Alkyl-Aryl sowie Cycloalkyl versteht man im Sinne dieser Erfindung unter ein- oder mehrfach substituiert die ein- oder mehrfache z.B. zwei-, drei- oder vierfache Substitution eines oder mehrerer Wasserstoffatome des Ringsystemes durch F, Cl, Br, I, CN, NH2, NH-Alkyl, NH-Aryl, NH-Heteroaryl, NH-Alkyl-Aryl, NH-Alkyl-Heteroaryl, NH-Heterocyclyl, NH-Alkyl-OH, N(Alkyl)2, NC(O)Alkyl, N(Alkyl-Aryl)2, N(Alkyl-Heteroaryl)2, N(Heterocyclyl)2, N(Alkyl-OH)2, NO, NO2, SH, S-Alkyl, S-Aryl, S-Heteroaryl, S-Alkyl-Aryl, S-Alkyl-Heteroaryl, S-Heterocyclyl, S-Alkyl-OH, S-Alkyl-SH, OH, O-Alkyl, O-Aryl, O-Heteroaryl, O-Alkyl-Aryl, O-Alkyl-Heteroaryl, O-Heterocyclyl, O-Alkyl-OH, O-C(O)-Alkyl, CHO, C(O)-Alkyl, C(S)-Alkyl, C(O)-Aryl, C(S)-Aryl, C(O)-Alkyl-Aryl, C(S)-Alkyl-Aryl, C(O)-Heterocyclyl, C(S)-Heterocyclyl, CO2H, CO2-Alkyl, CO2-Alkyl-aryl, C(O)-NH2, C(O)NH-Alkyl, C(O)NH-Aryl, C(O)NH-Heterocyclyl, C(O)N(Alkyl)2, C(O)N(Alkyl-Aryl)2, C(O)N(Alkyl-Heteroaryl)2, C(O)N(Heterocyclyl)2, SO-Alkyl, SO2-Alkyl, SO2-Aryl, SO2-Heteroaryl, SO2NH2, SO3H, CF3, CHO, CHS, Alkyl, Cycloalkyl, Aryl, Heteroaryl und/oder Heterocyclyl, an einem oder ggf. verschiedenen Atomen (wobei ein Substituent ggf. seinerseits substituiert sein kann). Die Mehrfachsubstitution erfolgt dabei mit dem gleichen oder mit unterschiedlichen Substituenten.With respect to aryl, heterocyclyl, heteroaryl, alkyl-aryl and cycloalkyl is understood in the context of this invention by mono- or polysubstituted one or more, for example two-, three- or four-fold substitution of one or more hydrogen atoms of the ring system by F, Cl , Br, I, CN, NH 2 , NH-alkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, N (alkyl) 2 , NC (O) alkyl, N (alkyl-aryl) 2 , N (alkyl-heteroaryl) 2 , N (heterocyclyl) 2 , N (alkyl-OH) 2 , NO, NO 2 , SH, S-alkyl, S-aryl , S-heteroaryl, S-alkyl-aryl, S-alkyl-heteroaryl, S-heterocyclyl, S-alkyl-OH, S-alkyl-SH, OH, O-alkyl, O-aryl, O-heteroaryl, O-alkyl -Aryl, O-alkyl-heteroaryl, O-heterocyclyl, O-alkyl-OH, OC (O) -alkyl, CHO, C (O) -alkyl, C (S) -alkyl, C (O) -aryl, C (S) -aryl, C (O) -alkyl-aryl, C (S) -alkyl-aryl, C (O) -heterocyclyl, C (S) -heterocyclyl, CO 2 H, CO 2 -alkyl, CO 2 - Alkyl-aryl, C (O) -NH 2 , C (O) -NH-alkyl, C (O) -NH-aryl, C (O) -NH-heterocyclyl, C (O) N (alkyl) 2 , C (O) N (alkyl-aryl) 2 , C (O ) N (alkyl-heteroaryl) 2 , C (O) N (heterocyclyl) 2 , SO-alkyl, SO 2 -alkyl, SO 2 -aryl, SO 2 -heteroaryl, SO 2 NH 2 , SO 3 H, CF 3 , CHO, CHS, alkyl, cycloalkyl, aryl, heteroaryl and / or heterocyclyl, on one or optionally different atoms (where a substituent may optionally be substituted in turn). The multiple substitution takes place with the same or different substituents.
Sofern die erfindungsgemäßen Verbindungen der allgemeinen Formel 1 mindestens ein Asymmetriezentrum aufweisen, können sie in Form ihrer Racemate, in Form der reinen Enantiomeren und/oder Diastereomeren oder in Form von Mischungen dieser Enantiomeren und/oder Diastereomeren vorliegen. Die Mischungen können in jedem beliebigen Mischungsverhältnis der Stereoisomeren vorliegen.Provided the compounds of the invention of general formula 1 have at least one center of asymmetry, can in the form of their racemates, in the form of pure enantiomers and / or Diastereomers or in the form of mixtures of these enantiomers and / or Diastereomers are present. The mixtures can be used in any mixing ratio Stereoisomers are present.
Sofern möglich, können die erfindungsgemäßen Verbindungen in Form der Tautomeren vorliegen.Provided possible, can the compounds of the invention in the form of the tautomers.
So lassen sich beispielsweise die erfindungsgemäßen Verbindungen gemäß der allgemeinen Formel 1, welche ein oder mehrere Chiralitätszentren aufweisen und die als Racemate auftreten, nach an sich bekannten Methoden in ihre optischen Isomeren, also Enantiomere oder Diastereomere auftrennen. Die Trennung kann durch Säulentrennung an chiralen Phasen oder durch Umkristallisation aus einem optisch aktiven Lösungsmittel oder unter Verwendung einer optisch aktiven Säure oder Base oder durch Derivatisierung mit einem optisch aktiven Reagenz, wie beispielsweise einem optisch aktiven Alkohol, und anschließender Abspaltung des Restes erfolgen.So can be, for example, the compounds of the invention according to the general Formula 1, which have one or more chiral centers and the occur as racemates, according to methods known per se in their optical isomers, ie enantiomers or diastereomers. The separation can be done by column separation on chiral phases or by recrystallization from an optical active solvents or using an optically active acid or base or by derivatization with an optically active reagent, such as an optical active alcohol, and subsequent Cleavage of the rest done.
Die erfindungsgemäßen Verbindungen der allgemeinen Formel 1 können, falls sie eine ausreichend basische Gruppe, wie zum Beispiel ein sekundäres oder tertiäres Amin besitzen, mit anorganischen und organischen Säuren in Salze überführt werden. Vorzugsweise werden die pharmazeutisch annehmbaren Salze der erfindungsgemäßen Verbindungen gemäß der allgemeinen Struktur 1 mit Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, p-Toluolsulfonsäure, Kohlensäure, Ameisensäure, Essigsäure, Sulfoessigsäure, Trifluoressigsäure, Oxasäure, Malonsäure, Maleinsäure, Bernsteinsäure, Weinsäure, Traubensäure, Äpfelsäure, Embonsäure, Mandelsäure, Fumarsäure, Milchsäure, Citronensäure, Taurocholinsäure, Glutaminsäure oder Asparaginsäure gebildet. Bei den gebildeten Salzen handelt es sich u.a. um Hydrochloride, Hydrobromide, Sulfate, Phosphate, Methansulfonate, Tosylate, Carbonate, Hydrogencarbonate, Formiate, Acetate, Sulfoacetate, Triflate, Oxalate, Malonate, Maleate, Succinate, Tartrate, Malate, Embonate, Mandelate, Fumarate, Lactate, Citrate und Glutaminate. Die Stöchiometrie der gebildeten Salze der erfindungsgemäßen Verbindungen kann dabei ganzzahlige oder nicht ganzzahlige Vielfache von eins betragen.The compounds of the general formula 1 according to the invention, if they have a sufficiently basic group, such as, for example, a secondary or tertiary amine, can be salified with inorganic and organic acids. Preferably, the pharmaceutically-acceptable salts of the compounds of the invention are of general structure 1 with hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, p-toluenesulfonic, carbonic, formic, acetic, sulfoacetic, trifluoroacetic, oxalic, malonic, maleic, succinic, tartaric, grape , Malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, taurocholic acid, glutamic acid or aspartic acid. The salts formed are, inter alia, hydrochlorides, hydrobromides, sulfates, phosphates, methanesulfonates, tosylates, carbonates, bicarbonates, formates, acetates, sulfoacetates, triflates, oxalates, malonates, maleates, succinates, tartrates, malates, embonates, Mandelates, Fumarates, Lactates, Citrates and Glutaminates. The stoichiometry of the formed salts of the compounds according to the invention can be integer or non-integer multiples of one.
Die erfindungsgemäßen Verbindungen der allgemeinen Formel 1 können, falls sie eine ausreichend saure Gruppe, wie zum Beispiel die Carboxygruppe, Sulfonsäure, Phosphorsäure oder eine phenolische Gruppe enthalten, mit anorganischen und organischen Basen in ihre physiologisch verträglichen Salze überführt werden. Als anorganische Basen kommen beispielsweise Natriumhydroxyd, Kaliumhydroxid, Calciumhydroxid, als organische Basen Ethanolamin, Diethanolamin, Triethanolamin, Cyclohexylamin, Dibenzylethylendiamin und Lysin in Betracht. Die Stöchiometrie der gebildeten Salze der erfindungsgemäßen Verbindungen kann dabei ganzzahlige oder nicht ganzzahlige Vielfache von eins betragen.The Compounds of the invention of general formula 1, if they have a sufficiently acidic group, such as the carboxy group, sulfonic acid, phosphoric acid or contain a phenolic group, with inorganic and organic Bases are converted into their physiologically acceptable salts. Examples of inorganic bases are sodium hydroxide, potassium hydroxide, Calcium hydroxide, as organic bases ethanolamine, diethanolamine, Triethanolamine, cyclohexylamine, dibenzylethylenediamine and lysine into consideration. The stoichiometry The formed salts of the compounds of the invention can thereby integer or non-integer multiples of one.
Ebenfalls bevorzugt sind Solvate und insbesondere Hydrate der erfindungsgemäßen Verbindungen, die z. B. durch Kristallisation aus einem Lösungsmittel oder aus wässriger Lösung erhalten werden können. Es können sich dabei ein, zwei, drei oder beliebig viele Solvat- oder Wasser-Moleküle mit den erfindungsgemäßen Verbindungen zu Solvaten und Hydraten verbinden.Also Solvates and in particular hydrates of the compounds according to the invention are preferred z. B. by crystallization from a solvent or from aqueous solution can be obtained. It can one, two, three, or any number of solvate or water molecules interact with the Compounds of the invention connect to solvates and hydrates.
Es ist bekannt, dass chemische Substanzen Festkörper ausbilden, die in verschiedenen Ordnungszuständen vorliegen, die man als polymorphe Formen oder Modifikationen bezeichnet. Die verschiedenen Modifikationen einer polymorphen Substanz können sich in ihren physikalischen Eigenschaften stark unterscheiden. Die erfindungsgemäßen Verbindungen der allgemeinen Formel 1 können in verschiedenen polymorphen Formen vorliegen, dabei können bestimmte Modifikationen metastabil sein.It It is known that chemical substances form solids which are in different forms ordered states present, which are referred to as polymorphic forms or modifications. The various modifications of a polymorphic substance can be differ greatly in their physical properties. The compounds of the invention the general formula 1 can in various polymorphic forms, there may be certain Modifications be metastable.
Am
meisten bevorzugt sind Verbindungen gemäß der allgemeinen Formel 1,
die in der folgenden Auswahl getroffen sind:
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methyl-pyridin-2yl)-piperazin-1yl]-methanon
(1)
Isopropylcarbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(2)
Essigsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(3)
Phosphorsäure
mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester (4)
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylestermethylester
(5)
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester-2-chlorethylester
(6)
(2-Hydroxy-ethyl)-carbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(7)
[4-(3-Chlorphenyl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon
(8)
[4-(6-Chlorpyridin-2yl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon
(9)
(1,3-Dihydroxy-acridin-9-yl)-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4yl)-methanon
(10)
Phosphorsäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester(11)
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methoxy-pyridin-2yl)-piperazin-1yl]-methanon
(12)
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanon
(13)
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-methoxyphenyl)-piperazin-1yl]-methanon
(14)
Methansulfonsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(15)
Kohlensäure-3-[4-(acridin-9-carbonyl)piperazin-1-yl]phenylester-2,2-dimethyl-[1,3]dioxolan-4-ylmethylester (16)
Phosphorsäure-3-(diphenoxy-phosphhoryloxy)-9-[4-(3-methoxyphenyl)-piperazin-1-carbonyl]-acridin-1-yl-esterdiphenylester
(17)
Essigsäure-3-acetoxy-9-[4-(3-methoxy-phenyl)-piperazin-1-carbonyl]-acridin-1-yl-ester (18)
Kohlensäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester
(19)Most preferred are compounds according to general formula 1 which are chosen in the following selection:
(1,3-Dihydroxy-acridin-9-yl) - [4- (6-methyl-pyridin-2yl) -piperazin-1-yl] -methanone (1)
Isopropylcarbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (2)
Acetic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (3)
Phosphoric acid mono- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester (4)
Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester methyl ester (5)
Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester 2-chloroethyl ester (6)
(2-Hydroxyethyl) -carbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (7)
[4- (3-Chlorophenyl) piperazin-1yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (8)
[4- (6-chloropyridin-2yl) -piperazin-1yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (9)
(1,3-Dihydroxy-acridin-9-yl) - (2,3,5,6-tetrahydro- [1,2 '] bipyrazinyl-4-yl) -methanone (10)
Phosphorsäurebis- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] phenyl} ester (11)
(1,3-Dihydroxy-acridin-9-yl) - [4- (6-methoxy-pyridin-2-yl) -piperazin-1-yl] -methanone (12)
(1,3-Dihydroxy-acridin-9-yl) - [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone (13)
(1,3-Dihydroxy-acridin-9-yl) - [4- (3-methoxyphenyl) -piperazin-1-yl] -methanone (14)
Methanesulfonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (15)
Carbonic acid 3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl ester 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester (16)
Phosphoric acid 3- (diphenoxy-phosphhoryloxy) -9- [4- (3-methoxyphenyl) -piperazine-1-carbonyl] -acridin-1-yl-esterdiphenyl ester (17)
Acetic acid 3-acetoxy-9- [4- (3-methoxy-phenyl) -piperazine-1-carbonyl] -acridin-1-yl-ester (18)
Carbonic acid bis {3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl} ester (19)
Gemäß einem weiteren Aspekt der Erfindung wird ein Verfahren zur Herstellung von Acridin-Derivaten, welches dadurch gekennzeichnet ist, daß eine Acridincarbonsäure der allgemeinen Formel 2, worin R, R1, R2, R3 die vorstehend genannten Bedeutungen besitzen, Z ein Sauerstoff- oder Schwefelatom bedeutet und Y für eine Abgangsgruppe wie Halogen, Hydroxy, (C1-C6)-Alkoxy vorzugsweise Methoxy und Ethoxy, -O-Tosyl, -O-Mesyl, Tetrazolyl oder Imidazolyl steht, mit einem Amin der allgemeinen Formel 3, worin R4, m und n die vorstehend genannten Bedeutungen besitzen, gegebenenfalls unter Verwendung eines Kondensationsmittels und/oder Katalysators sowie von Verdünnungs- und Hilfsmitteln unter Bildung der gewünschten Acridin-Derivate umgesetzt wird.According to a further aspect of the invention, a process for the preparation of acridine derivatives, which is characterized in that an acridine carboxylic acid of the general formula 2, wherein R, R 1 , R 2 , R 3 have the meanings given above, Z is an oxygen or is sulfur atom and Y is a leaving group such as halogen, hydroxy, (C 1 -C 6 ) -alkoxy, preferably methoxy and ethoxy, -O-tosyl, -O-mesyl, tetrazolyl or imidazolyl, with an amine of the general formula 3, wherein R 4 , m and n have the abovementioned meanings, if appropriate using a condensing agent and / or catalyst as well as diluents and auxiliaries to form the desired acridine derivatives.
Synthese der erfindungsgemäßen VerbindungenSynthesis of the compounds of the invention
Die Verbindungen der allgemeinen Formel 1 sind beispielsweise gemäß den folgenden Schemen 1, 2 und 3 erhältlich: Schema 1 Schema 2 Schema 3 The compounds of general formula 1 are obtainable, for example, according to the following schemes 1, 2 and 3: Scheme 1 Scheme 2 Scheme 3
Die Ausgangsverbindungen 2 und 3 sind entweder im Handel erhältlich oder können nach an sich bekannten Verfahrensweisen hergestellt werden. Die Edukte 2 und 3 stellen wertvolle Zwischenverbindungen für die Herstellung der erfindungsgemäßen Acridin-Derivate der Formel 1 dar.The Starting compounds 2 and 3 are either commercially available or can be prepared according to known procedures. The Educts 2 and 3 provide valuable intermediates for the preparation the acridine derivatives according to the invention of formula 1
Die gegebenenfalls zu verwendenden Lösungs- und Hilfsmittel und anzuwendenden Reaktionsparameter wie Reaktionstemperatur und -dauer sind dem Fachmann aufgrund seines Fachwissens bekannt.The optionally used solution and auxiliaries and reaction parameters to be used, such as reaction temperature and duration are known to those skilled in the art due to its expertise.
Die erfindungsgemäßen Acridin-Derivate gemäß der allgemeinen Formel 1 sind als Wirkstoffe in Arzneimitteln, insbesondere als Antitumormittel, zur Behandlung von Menschen und Säugetieren geeignet. Säugetiere können Haustiere wie Pferde, Kühe, Hunde, Katzen, Hasen, Schafe und dergleichen sein.The Acridine derivatives according to the invention according to the general Formula 1 are used as active ingredients in medicines, in particular as Antitumor agents for the treatment of humans and mammals suitable. mammals can Pets like horses, cows, Dogs, cats, rabbits, sheep and the like.
Die medizinische Wirkung der erfindungsgemäßen Acridin-Derivate kann zum Beispiel auf einer Wechselwirkung mit dem Tubulin-System durch Hemmung der Tubulin-Polymerisation beruhen. Daneben sind noch weitere bekannte und unbekannte Wirkmechanismen zur Bekämpfung der Tumurzellen denkbar.The Medical effect of the acridine derivatives according to the invention can for Example of an interaction with the tubulin system by inhibition based on tubulin polymerization. There are also other well-known ones and unknown mechanisms of action to combat tumor cells conceivable.
Gemäß einem weiteren Aspekt der Erfindung wird ein Verfahren zur Bekämpfung von Tumoren beim Menschen und in Säugetieren bereit gestellt, welches dadurch gekennzeichnet ist, daß mindestens ein Acridin-Derivat gemäß der allgemeinen Formel 1 dem Menschen oder einem Säugetier in einer für die Tumorbehandlung wirksamen Menge verabreicht wird. Die für die Behandlung zu verabreichende therapeutisch effektive Dosis des jeweiligen erfindungsgemäßen Acridin-Derivates richtet sich u.a. nach der Art und dem Stadium der Tumorerkrankung, dem Alter und Geschlecht des Patienten, der Art der Verabreichung und der Dauer der Behandlung. Die erfindungsgemäßen Arzneimittel können als flüssige, halbfeste und feste Arzneiformen verabreicht werden. Dies erfolgt in der jeweils geeigneten Weise in Form von Aerosolen, Pulver, Puder und Streupuder, Tabletten, Dragees, Emulsionen, Schäume, Lösungen, Suspensionen, Gele, Salben, Pasten, Pillen, Pastillen, Kapseln oder Suppositorien.According to one Another aspect of the invention is a method of combating Tumors in humans and in mammals provided, which is characterized in that at least an acridine derivative according to the general Formula 1 to the human or a mammal in a tumor treatment effective amount is administered. The to be administered for the treatment therapeutically effective dose of the particular acridine derivative according to the invention is aimed, inter alia. according to the type and stage of the tumor disease, the age and sex of the patient, the mode of administration and the duration of the treatment. The medicaments according to the invention can be described as liquid, semi-solid and solid dosage forms are administered. this happens in the appropriate manner in the form of aerosols, powder, powder and scattering powders, tablets, dragees, emulsions, foams, solutions, Suspensions, gels, ointments, pastes, pills, lozenges, capsules or Suppositories.
Die Arzneiformen enthalten neben mindestens einem erfindungsgemäßen Bestandteil je nach eingesetzter galenischer Form gegebenenfalls Hilfsstoffe, wie unter anderem Lösungsmittel, Lösungsbeschleuniger, Lösungsvermittler, Emulgatoren, Netzmittel, Antischaummittel, Gelbildner, Verdickungsmittel, Filmbildner, Bindemittel, Puffer, Salzbildner, Trocknungsmittel, Fließregulierungsmittel, Füllstoffe, Konservierungsstoffe, Antioxidatien, Farbstoffe, Formentrennmittel, Gleitmittel, Sprengmittel, Geschmacks- und Geruchskorrigentien. Die Auswahl der Hilfsstoffe sowie die einzusetzenden Mengen derselben hängt von der gewählten galenischen Form ab und orientiert sich an die dem Fachmann bekannten Rezepturen.In addition to at least one component according to the invention, the dosage forms optionally contain auxiliaries, depending on the galenic form used, such as, inter alia, solvents, dissolution accelerators, solubilizers, emulsifiers, wetting agents, antifoams, gelling agents, thickeners, film formers, bin agents, buffers, salt formers, drying agents, flow regulators, fillers, preservatives, antioxidants, dyes, mold release agents, lubricants, disintegrants, flavor and odor remedies. The choice of excipients and the amounts to be used depend on the galenical form chosen and are based on the formulations known to the person skilled in the art.
Die erfindungsgemäßen Arzneimittel können in einer geeigneten Darreichungsform auf die Haut, epicutan als Lösung, Suspension, Emulsion, Schaum, Salbe, Paste oder Pflaster; über die Mund- und Zungenschleimhaut, buccal, lingual oder sublingual als Tablette, Pastille, Dragees, Linctus oder Gurgelwasser; über die Magen- und Darmschleimhaut, enteral als Tablette, Dragees, Kapsel, Lösung, Suspension oder Emulsion; über die Rectumschleimhaut, rectal als Suppositorium, Rectalkapsel oder Salbe; über die Nasenschleimhaut, nasal als Tropfen, Salben oder Spray; über das Bronchial- und Alveolarepithel, pulmonal oder per inhalationem als Aerosol oder Inhalat; über die Conjunctiva, conjunctival als Augentropfen, Augensalbe, Augentabletten, Lamellae oder Augenwasser; über die Schleimhäute der Genitalorgane, intravaginal als Vaginalkugeln, Salben und Spülung, intrauterin als Uterus-Pessare; über die ableitenden Harnwege, intraurethral als Spülung, Salbe oder Arzneistäbchen; in eine Arterie, intraarteriell als Injektion; in eine Vene, intravenös als Injektion oder Infusion, paravenös als Injektion oder Infusion; in die Haut, intracutan als Injektion oder Implantat; unter die Haut, subcutan als Injektion oder Implantat; in den Muskel, intramusculär als Injektion oder Implantat; in die Bauchhöhle, intraperitoneal als Injektion oder Infusion verabreicht werden.The medicaments of the invention can in a suitable dosage form on the skin, epicutane as Solution, Suspension, emulsion, foam, ointment, paste or plaster; about the Mouth and tongue mucosa, buccal, lingual or sublingual Tablet, troche, dragees, linctus or gargles; about the Gastrointestinal mucosa, enteral as tablet, dragees, capsule, Solution, Suspension or emulsion; above the rectum mucosa, rectal as a suppository, rectal capsule or Ointment; above the nasal mucosa, nasally as drops, ointments or spray; about the Bronchial and alveolar epithelium, pulmonary or by inhalation Aerosol or inhalant; above the conjunctiva, conjunctival as eye drops, eye ointment, eye tablets, Lamellae or eye water; above the mucous membranes of the genital organs, intra vaginal as vaginal balls, ointments and rinses, intrauterine as uterine pessaries; above the draining urinary tract, intraurethrally as a conditioner, ointment or medicament sticks; in an artery, intraarterially as an injection; into a vein, intravenously as an injection or infusion, paravenous as an injection or infusion; into the skin, intracutaneously as an injection or implant; under the skin, subcutaneously as an injection or implant; into the muscle, intramuscular as an injection or implant; into the abdominal cavity, intraperitoneally as an injection or infusion.
Die erfindungsgemässen Verbindungen der allgemeinen Struktur 1 können in Hinblick auf praktische therapeutische Erfordernisse mittels geeigneter Maßnahmen in ihrer Arzneistoffwirkung verlängert werden. Dieses Ziel kann auf chemischem und/oder galenischem Wege erreicht werden. Beispiele für die Erzielung einer Wirkungsverlängerung sind der Einsatz von Implantaten, Liposomen, Retardformen, Nanopartikelsuspensionen und so genannter Prodrugs der erfindungsgemäßen Verbindungen, die Bildung von schwerlöslichen Salzen und Komplexen oder der Einsatz von Kristall-Suspensionen.The invention Compounds of general structure 1 may be useful in terms of practical therapeutic Requirements by means of appropriate measures in their drug effect extended become. This goal can be achieved chemically and / or galenically be achieved. examples for the achievement of an effect extension are the use of implants, liposomes, sustained release forms, nanoparticle suspensions and so-called prodrugs of the compounds of the invention, the formation of sparingly soluble salts and complexes or the use of crystal suspensions.
Die erfindungsgemäßen Verbindungen der allgemeinen Struktur 1 können als Einzelsubstanz oder in Kombination mit weiteren cytotoxischen Substanzen, wie z.B. Cisplatin, Carboplatin, Doxorubicin, Ifosfamid, Cyclophosphamid, 5-FU, Methotrexat bzw. in Kombination mit Immunomodulatoren oder Antikörpern und insbesondere in Kombination mit Hemmstoffen der Signaltransduktion , wie z.B. Herceptin, Glivec oder Iressa eingesetzt werden.The Compounds of the invention of the general structure 1 as a single substance or in combination with other cytotoxic Substances, e.g. Cisplatin, carboplatin, doxorubicin, ifosfamide, cyclophosphamide, 5-FU, methotrexate or in combination with immunomodulators or antibodies and especially in combination with signal transduction inhibitors , such as. Herceptin, Glivec or Iressa.
Besonders
bevorzugt sind dabei Arzneimittel, die mindestens eine Verbindung
aus der nachfolgenden Gruppe der Arylderivate enthalten:
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methyl-pyridin-2yl)-piperazin-1yl]-methanon
(1)
Isopropylcarbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(2)
Essigsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(3)
Phosphorsäure
mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester (4)
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylestermethylester
(5)
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester-2-chlorethylester
(6)
(2-Hydroxy-ethyl)-carbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(7)
[4-(3-Chlorphenyl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon
(8)
[4-(6-Chlorpyridin-2yl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon
(9)
(1,3-Dihydroxy-acridin-9-yl)-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4yl)-methanon
(10)
Phosphorsäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester
(11)
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methoxy-pyridin-2yl)-piperazin-1yl]-methanon
(12)
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanon
(13)
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-methoxyphenyl)-piperazin-1yl]-methanon
(14)
Methansulfonsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(15)
Kohlensäure-3-[4-(acridin-9-carbonyl)piperazin-1-yl]phenylester-2,2-dimethyl[1,3]dioxolan-4-ylmethylester (16)
Phosphorsäure-3-(diphenoxy-phosphhoryloxy)-9-[4-(3-methoxyphenyl)-piperazin-1-carbonyl]-acridin-1-yl-esterdiphenylester
(17)
Essigsäure-3-acetoxy-9-[4-(3-methoxy-phenyl)-piperazin-1-carbonyl]-acridin-1-yl-ester (18)
Kohlensäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester
(19)
und sowohl als freie Base als auch als Salze physiologisch
verträglicher
Säuren
vorliegen können.Particularly preferred are medicaments which contain at least one compound from the following group of aryl derivatives:
(1,3-Dihydroxy-acridin-9-yl) - [4- (6-methyl-pyridin-2yl) -piperazin-1-yl] -methanone (1)
Isopropylcarbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (2)
Acetic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (3)
Phosphoric acid mono- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester (4)
Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester methyl ester (5)
Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester 2-chloroethyl ester (6)
(2-Hydroxyethyl) -carbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (7)
[4- (3-Chlorophenyl) piperazin-1yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (8)
[4- (6-chloropyridin-2yl) -piperazin-1yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (9)
(1,3-Dihydroxy-acridin-9-yl) - (2,3,5,6-tetrahydro- [1,2 '] bipyrazinyl-4-yl) -methanone (10)
Phosphoric acid bis {3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl} ester (11)
(1,3-Dihydroxy-acridin-9-yl) - [4- (6-methoxy-pyridin-2-yl) -piperazin-1-yl] -methanone (12)
(1,3-Dihydroxy-acridin-9-yl) - [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone (13)
(1,3-Dihydroxy-acridin-9-yl) - [4- (3-methoxyphenyl) -piperazin-1-yl] -methanone (14)
Methanesulfonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (15)
Carbonic acid 3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl ester 2,2-dimethyl [1,3] dioxolan-4-ylmethyl ester (16)
Phosphoric acid 3- (diphenoxy-phosphhoryloxy) -9- [4- (3-methoxyphenyl) -piperazine-1-carbonyl] -acridin-1-yl-esterdiphenyl ester (17)
Acetic acid 3-acetoxy-9- [4- (3-methoxy-phenyl) -piperazine-1-carbonyl] -acridin-1-yl-ester (18)
Carbonic acid bis {3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl} ester (19)
and may be present both as a free base and as salts of physiologically acceptable acids.
Gemäß dieser allgemeinen Vorschrift für die Stufen 1, 2 und 3, denen die Syntheseschemata 1, 2 und 3 zugrunde liegen, wurden folgende Verbindungen synthetisiert, die unter der Angabe der jeweiligen chemischen Bezeichnung aus der nachfolgenden Übersicht hervorgehen. Die analytische Charakterisierung der erfindungsgemäßen Verbindungen erfolgte durch ihre Schmelzpunkte bzw. 1H- und 3P-NMR-spektroskopisch und/oder massenspektrometrisch.In accordance with this general procedure for stages 1, 2 and 3, which are based on the synthesis schemes 1, 2 and 3, the following compounds were synthesized, which show the chemical overview given below from the overview. The analytical characterization of he compounds according to the invention was carried out by their melting points or 1 H and 3P NMR spectroscopy and / or mass spectrometry.
Die eingesetzten Chemikalien und Lösungsmittel wurden kommerziell bei den herkömmlichen Anbietern erworben (Acros, Avocado, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCl etc.) oder synthetisiert.The used chemicals and solvents became commercial in the conventional ones Vendors (Acros, Avocado, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCl etc.) or synthesized.
Die Erfindung soll anhand der nachfolgenden Beispiele näher erläutert werden, ohne darauf beschränkt zu sein.The Invention will be explained in more detail with reference to the following examples, without limitation to be.
Beispiel 1 (Umsetzung gemäß Schema 1, Variante 1):Example 1 (Reaction according to the scheme 1, variant 1):
Acridin-9-yl-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanonAcridine-9-yl- [4- (3-hydroxyphenyl) piperazin-1-yl] -methanone
Eine
Lösung
von 3 g (13.44 mMol) Acridin-9-carbonsäure Hydrat in 30 ml Dimethylformamid
wurde nacheinander mit 2.17 g (21.5 mMol) N-Methylmorpholin, 2.4
g (13.44 mMol) N-(3-Hydroxyphenylpiperazin und 7.69 g (14.78 mMol)
Py-BOP 1-Benzotriazolyl-tripyrrolidinophosphoniumhexafluorphosphat)
versetzt. Man rührte
4 Stunden bei Raumtemperatur, ließ über Nacht bei Raumtemperatur
stehen, destillierte Dimethylformamid i. Vak. ab und reinigte den
Rückstand über eine
Kieselgelsäule
(Kieselgel 60, Fa. Merck AG, Darmstadt) unter Anwendung des Elutionsmittels
Dichlormethan/Methanol (95:5 V/V).
Ausbeute: 3.01 g (57.8%
d. Th.)
Fp.: 143°CA solution of 3 g (13.44 mmol) of acridine-9-carboxylic acid hydrate in 30 ml of dimethylformamide was added sequentially with 2.17 g (21.5 mmol) of N-methylmorpholine, 2.4 g (13.44 mmol) of N- (3-hydroxyphenylpiperazine and 7.69 g (14.78 mmol ) Py-BOP 1-benzotriazolyl-tripyrrolidinophosphonium hexafluorophosphate). The mixture was stirred for 4 hours at room temperature, allowed to stand overnight at room temperature, distilled dimethylformamide i. Vak. and the residue was purified on a silica gel column (Kieselgel 60, Merck AG, Darmstadt) using the eluent dichloromethane / methanol (95: 5 v / v).
Yield: 3.01 g (57.8% of theory)
Mp .: 143 ° C
Beispiel 2 (Umsetzung gemäß Schema 1, Variante 2):Example 2 (Reaction according to the scheme 1, variant 2):
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methyl-pyridin-2yl)-piperazin-1yl]-methanon (1)(1,3-dihydroxy-acridin-9-yl) - [4- (6-methyl-pyridin-2-yl) piperazin-1-yl] -methanone (1)
Eine
Lösung
von 1.8 g (7.05 mMol) 1,3-Dihydroxyacridin-9-carbonsäure in 40
ml Dimethylformamid wurde mit 6.66 g (11.06 mMol) polymergebundenem
N-Benzyl-N-cyclohexylcarbodiimid
(1.66 mMol/g) versetzt, auf 60°C
erwärmt
und 30 Minuten miteinander zur Reaktion gebracht. Hierzu gab man
1.03 g (5.64 mMol) von 1-(2-(6-Methylpyridinyl))piperazin
und für
weitere 4 Stunden reagieren. Danach lies man Abkühlen, trennte vom Harz ab,
destillierte das Dimethylformamid i. Vak. ab und reinigte den Rückstand über eine
Kieselgelsäule
(Kieselgel 60, Fa. Merck AG, Darmstadt) unter Anwendung des Elutionsmittels
Dichlormethan/Methanol (95:5 V/V).
Ausbeute: 2.3 g (74.8% d.
Th.)
1H-NMR (DMSO-d6) δ = 10.9 (s,
1H), 10.3 (s, 1H), 7.97 (d, 1H), 7.84 (d, 1H), 7.75 (t, 1H), 7.5-7.4
(m, 2H), 6.86 (d, 1H), 6.61 (d, 1H), 6.56 (d, 1H), 4.05 (m, 1H),
3.8 (m, 1H), 3.7 (m, 1H), 3.6 (m, 1H), 3.5 (m, 1H), 3.15 (m, 1H),
3.05 (m, 2H), 2.25 (s, 3H) ppm.To a solution of 1.8 g (7.05 mmol) of 1,3-dihydroxyacridine-9-carboxylic acid in 40 ml of dimethylformamide was added 6.66 g (11.06 mmol) of polymer-bound N-benzyl-N-cyclohexylcarbodiimide (1.66 mmol / g) to 60 ° C heated and reacted with each other for 30 minutes. To this was added 1.03 g (5.64 mmol) of 1- (2- (6-methylpyridinyl)) piperazine and allowed to react for a further 4 hours. Then allowed to cool, separated from the resin, distilled the dimethylformamide i. Vak. and the residue was purified on a silica gel column (Kieselgel 60, Merck AG, Darmstadt) using the eluent dichloromethane / methanol (95: 5 v / v).
Yield: 2.3 g (74.8% of theory)
1 H-NMR (DMSO-d6) δ = 10.9 (s, 1H), 10.3 (s, 1H), 7.97 (d, 1H), 7.84 (d, 1H), 7.75 (t, 1H), 7.5-7.4 ( m, 2H), 6.86 (d, 1H), 6.61 (d, 1H), 6.56 (d, 1H), 4.05 (m, 1H), 3.8 (m, 1H), 3.7 (m, 1H), 3.6 (m , 1H), 3.5 (m, 1H), 3.15 (m, 1H), 3.05 (m, 2H), 2.25 (s, 3H) ppm.
Beispiel 3 (Umsetzung gemäß Schema 2):Example 3 (Reaction according to the scheme 2):
Isopropylcarbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester (2)Isopropylcarbaminsäure-3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (2)
Eine
Suspension von 100 mg (0.26 mMol) Acridin-9-yl-[4-(3-hydroxyphenyl)piperazin-1-yl]-methanon in
15 ml Dichlormethan wurde sukzessiv mit 40 μl (0.39 mMol) Triethylamin und
24 μl (0.29
mMol) Isoproyplisocyanat versetzt. Nach 18 h Rühren bei Raumtemperatur wurde
das Lösungsmittel
i. Vak. entfernt und der Rückstand über eine
Kieselgelsäule
unter Anwendung des Elutionsmittels Dichlormethan/Methanol (99:1
V/V) gereinigt.
Ausbeute: 95 mg (78% d. Th.).
Fp.: 197–198°C.
1H-NMR (DMSO-d6) δ = 8.24 (d,
2H), 7.99 (d, 2H), 7.91 (dd, 2H), 7.71 (dd, 2H), 7.59 (d, 1H), 7.18
(dd, 1H), 6.75 (dd, 1H), 6.62 (s, 1H), 6.52 (d, 1H), 4.10-4.12 (m,
2H), 3.59-3.65 (m, 1H), 3.46-3.48 (m, 2H), 3.10-3.12 (m, 2H), 2.95-2.97
(m, 2H), 1.10 (d, 6H) ppm.A suspension of 100 mg (0.26 mmol) of acridin-9-yl- [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone in 15 ml of dichloromethane was successively mixed with 40 μl (0.39 mmol) of triethylamine and 24 μl (0.29 mmol) Isoproyplisocyanat. After stirring for 18 h at room temperature, the solvent was i. Vak. and the residue was purified on a silica gel column using the eluent dichloromethane / methanol (99: 1 v / v).
Yield: 95 mg (78% of theory).
Mp .: 197-198 ° C.
1 H-NMR (DMSO-d 6) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.91 (dd, 2H), 7.71 (dd, 2H), 7:59 (d, 1H), 7.18 (dd , 1H), 6.75 (dd, 1H), 6.62 (s, 1H), 6.52 (d, 1H), 4.10-4.12 (m, 2H), 3.59-3.65 (m, 1H), 3.46-3.48 (m, 2H ), 3.10-3.12 (m, 2H), 2.95-2.97 (m, 2H), 1.10 (d, 6H) ppm.
Beispiel 4 (Umsetzung gemäß Schema 2):Example 4 (Reaction according to the scheme 2):
Essigsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester (3)Acetic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (3)
Eine
Suspension von 100 mg (0.26 mMol) Acridin-9-yl-[4-(3-hydroxyphenyl)piperazin-1-yl]-methanon in
15 ml Dichlormethan wurde sukzessiv mit 40 μl (0.39 mMol) Triethylamin und
27 μl (29
mMol) Essigsäureanhydrid
versetzt. Nach 18 h Rühren
bei Raumtemperatur wurde das Lösungsmittel
i. Vak. entfernt und der Rückstand über eine
Kieselgelsäule
unter Anwendung des Elutionsmittels Dichlormethan/Methanol (99:1
V/V) gereinigt.
Ausbeute: 81 mg (73% d. Th.).
Fp.: 162°C.
1H-NMR (DMSO-d6) δ = 8.24 (d,
2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.22 (dd, 1H),
6.81 (dd, 1H), 6.67 (s, 1H), 6.54 (dd, 1H), 4.10-4.12 (m, 2H), 3.47-3.50
(m, 2H), 3.10-3.13 (m, 2H), 2.95-2.98 (m, 2H), 2.22 (s, 3H) ppm.A suspension of 100 mg (0.26 mmol) of acridin-9-yl- [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone in 15 ml of dichloromethane was successively mixed with 40 μl (0.39 mmol) of triethylamine and 27 μl (29 mmol) acetic anhydride. After stirring for 18 h at room temperature, the solvent was i. Vak. and the residue was purified on a silica gel column using the eluent dichloromethane / methanol (99: 1 v / v).
Yield: 81 mg (73% of theory).
Mp .: 162 ° C.
1 H-NMR (DMSO-d 6) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.22 (dd, 1H), 6.81 (dd , 1H), 6.67 (s, 1H), 6.54 (dd, 1H), 4.10-4.12 (m, 2H), 3.47-3.50 (m, 2H), 3.10-3.13 (m, 2H), 2.95-2.98 (m , 2H), 2.22 (s, 3H) ppm.
Beispiel 5 (Umsetzung gemäß Schema 2):Example 5 (Reaction according to the scheme 2):
Phosphorsäure mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester (4)Phosphoric acid mono- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester (4)
Eine Lösung von 364 mg (0.94 mMol) Acridin-9-yl-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanon in 10 ml Pyridin wurde mit 360 mg (1.90 mMol) Phosphorsäure-bis-(dimethylamid)-Chlorid, 214 mg (1.4 mMol) DBU und 232 g (1.90 mMol) DMAP bei Raumtemperatur 2 Stunden zur Reaktion gebracht. Die Reaktionslösung wurde anschliessend im Vakuum eingeengt, wobei ein braunes Öl als Rückstand resultierte. Das Rohprodukt wurde in wenig DMF gelöst und durch zweimalige Säulenchromatographie gereinigt (Geduran Si 60, Säule L 280, (/) 25, Eluens 95 DCM + 5 McOH). Man erhielt 433 mg Phosphorsäure-bis-(dimethylamid)-mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester in einer Reinheit von 88%.A solution of 364 mg (0.94 mmol) of acridin-9-yl [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone in 10 ml Pyridine was treated with 360 mg (1.90 mmol) of phosphoric acid bis (dimethylamide) chloride, 214 mg (1.4 mmol) DBU and 232 g (1.90 mmol) of DMAP at room temperature for 2 hours reacted. The reaction solution was then in Vacuum evaporated, resulting in a brown oil as a residue. The crude product was solved in a little DMF and by two-times column chromatography purified (Geduran Si 60, column L 280, (/) 25, Eluens 95 DCM + 5 McOH). 433 mg of phosphoric acid bis (dimethylamide) mono- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester were obtained in a purity of 88%.
370 mg vom Phosphorsäure-bis-(dimethylamid)-mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester wurden anschliessend in 1 ml Wasser und 9 ml TFA aufgenommen und 2h bei Raumtemperatur gerührt.370 Phosphoric acid bis (dimethylamide) mono- {3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl} ester were then taken up in 1 ml of water and 9 ml of TFA and Stirred for 2 h at room temperature.
Die
Reaktionslösung
wurde nachfolgend im Vakuum eingeengt und lyophilisiert. Der Rückstand
wurde durch präparative
Hochdruckchromatographie gereinigt (HPLC – JO, RP18, 250-50, 12 μm, Fluß 60 ml/min; 10%
B–100%
B in 30 min), wobei 315 mg Phosphorsäure mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester
anfielen.
Ausbeute: 315 mg (84.7% d. Th.)
M: 463 g/mol;
gefundene Molmasse 464.1 [M + H]+
1H-NMR (DMSO-d6): δ = 8.24 (d,
2H), 8.00 (d, 2H), 7.93 (t, 2H), 7.72 (t, 2H), 7.16 (t, 1H), 6.71
(d, 1H), 6.68 (s, 1H), 6.63 (d, 1H), 4.13-4.11 (m, 2H), 3.47-3.45
(m, 2H), 3.14-3.12 (m, 2H), 2.95-2.93 (m, 2H).
31P-NMR
(DMSO-d6): δ = –6.44 ppmThe reaction solution was subsequently concentrated in vacuo and lyophilized. The residue was purified by preparative high pressure chromatography (HPLC-JO, RP18, 250-50, 12 μm, flow 60 ml / min, 10% B-100% B in 30 min), giving 315 mg of phosphoric acid mono- {3- [4 - (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester incurred.
Yield: 315 mg (84.7% of theory)
M: 463 g / mol; found molar mass 464.1 [M + H] +
1 H-NMR (DMSO-d 6 ): δ = 8.24 (d, 2H), 8.00 (d, 2H), 7.93 (t, 2H), 7.72 (t, 2H), 7.16 (t, 1H), 6.71 ( d, 1H), 6.68 (s, 1H), 6.63 (d, 1H), 4.13-4.11 (m, 2H), 3.47-3.45 (m, 2H), 3.14-3.12 (m, 2H), 2.95-2.93 ( m, 2H).
31 P-NMR (DMSO-d 6 ): δ = -6.44 ppm
Beispiel 6 (Umsetzung gemäß Schema 2):Example 6 (Reaction according to the scheme 2):
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylestermethylester (5)Carbonic acid-3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenylestermethylester (5)
Eine
Suspension von 100 mg (0.26 mMol) Acridin-9-yl-[4-(3-hydroxyphenyl)piperazin-1-yl]-methanon in
15 ml Dichlormethan wurde sukzessiv mit 40 μl (0.39 mMol) Triethylamin und
22 μl (0.29
mMol) Methylchloroformiat versetzt. Nach 18 h Rühren bei Raumtemperatur wurde
das Lösungsmittel
i. Vak. entfernt und der Rückstand über eine
Kieselgelsäule
unter Anwendung des Elutionsmittels Dichlormethan/Methanol (99:1
V/V) gereinigt.
Ausbeute: 99 mg (86.0 % d. Th.).
Fp.:
183–184°C.
1H-NMR (DMSO-d6) δ = 8.24 (d,
2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.24 (dd, 1H),
6.84 (dd. 1H), 6.78 (s, 1H), 6.64 (dd, 1H), 4.10-4.12 (m, 2H), 3.80
(s, 3H), 3.49-3.52 (m, 2H), 3.10-3.13 (m, 2H), 2.97-3.00 (m, 2H)
ppm.A suspension of 100 mg (0.26 mmol) of acridin-9-yl- [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone in 15 ml of dichloromethane was successively mixed with 40 μl (0.39 mmol) of triethylamine and 22 μl (0.29 mmol) of methyl chloroformate. After stirring for 18 h at room temperature, the solvent was i. Vak. and the residue was purified on a silica gel column using the eluent dichloromethane / methanol (99: 1 v / v).
Yield: 99 mg (86.0% of theory).
Mp .: 183-184 ° C.
1 H-NMR (DMSO-d 6 ) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.24 (dd, 1H), 6.84 (dd 1H), 6.78 (s, 1H), 6.64 (dd, 1H), 4.10-4.12 (m, 2H), 3.80 (s, 3H), 3.49-3.52 (m, 2H), 3.10-3.13 (m, 2H ), 2.97-3.00 (m, 2H) ppm.
Beispiel 7 (Umsetzung gemäß Schema 2):Example 7 (Reaction according to the scheme 2):
Methansulfonsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester (15)Methanesulfonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (15)
Eine
Lösung
von 0.15 g (0.39 mMol) Acridin-9-yl-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanon in 15 ml
Pyridin wurde mit 0.07 g (0.59 mMol) Methansulfonsäurechlorid
bei Raumtemperatur 4 Stunden zur Reaktion gebracht. Danach destillierte
man das Pyridin i. Vak. ab und reinigte den Rückstand über eine Kieselgelsäule (Kieselgel
60, Fa. Merck AG, Darmstadt) unter Anwendung des Elutionsmittels
Dichlormethan/Methanol (95:5 V/V).
Ausbeute: 8 mg (4.1% d.
Th.)
1H-NMR (DMSO-d6) δ = 8.25 (d,
2H), 7.9-8.05 (m, 5H), 7.7 (t, 2H), 7.3 (t, 1H), 6.95 (d, 1H), 6.75
(d, 1H), 4.13 (m, 2H), 3.55 (m, 2H), 3.33 (s, 3H), 3.12 (m, 2H),
3.05 (m, 2H) ppm.A solution of 0.15 g (0.39 mmol) of acridin-9-yl- [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone in 15 ml of pyridine was reacted with 0.07 g (0.59 mmol) of methanesulfonyl chloride at room temperature for 4 hours , Thereafter, the pyridine was distilled i. Vak. and the residue was purified on a silica gel column (Kieselgel 60, Merck AG, Darmstadt) using the eluent dichloromethane / methanol (95: 5 v / v).
Yield: 8 mg (4.1% of theory)
1 H-NMR (DMSO-d 6 ) δ = 8.25 (d, 2H), 7.9-8.05 (m, 5H), 7.7 (t, 2H), 7.3 (t, 1H), 6.95 (d, 1H), 6.75 (d, 1H), 4.13 (m, 2H), 3.55 (m, 2H), 3.33 (s, 3H), 3.12 (m, 2H), 3.05 (m, 2H) ppm.
Beispiel 8 (Umsetzung gemäß Schema 3):Example 8 (Reaction according to the scheme 3):
Phosphorsäure-3-(diphenoxy-phosphoryloxy)-9-[4-(3-methoxyphenyl)-piperazin-1-carbonyl]-acridin-1-yl-esterdiphenylester (17)Phosphoric acid-3- (diphenoxy-phosphoryloxy) -9- [4- (3-methoxyphenyl) -piperazine-1-carbonyl] acridine-1-yl-esterdiphenylester (17)
Eine
Lösung
von 0.46 g (1.1 mMol) (1,3-Dihydroxy-acridin-9-yl)-[4-(3-methoxyphenyl)-piperazin-1yl]-methanon
in 30 ml Pyridin wurde auf T = –10°C abgekühlt und
bei dieser Temperatur mit 0.72 g (2.68 mMol) Diphenylchlorphosphat
und 0.58 g (4.5 mMol) Diisopropylethylamin 1.5 Stunden zur Reaktion
gebracht. Anschliessend verdünnte
man den Ansatz mit 10 m1 Dichlormethan und extrahierte dreimal mit
jeweils 10 ml Wasser. Das Lösungsmittel
der organischen Phase destillierte man i. Vak. ab und reinigte den
Rückstand über eine
Kieselgelsäule
(Kieselgel 60, Fa. Merck AG, Darmstadt) unter Anwendung des Elutionsmittels
Dichlormethan/Methanol (97:3 V/V).
Ausbeute: 134 mg (13.3%
d. Th.)
1H-NMR (DMSO-d6) δ = 8.25 (d,
1H), 8.06-8.0 (m, 3H), 7.78 (m, 2H), 7.46-7.23 (m, 22H), 7.1 (t,
1H), 6.42 (m, 1H), 3.7-3.1 (m, 11H) ppm.
31P-NMR
(DMSO-d6): δ = –18.2, –17.8 ppmA solution of 0.46 g (1.1 mmol) of (1,3-dihydroxy-acridin-9-yl) - [4- (3-methoxyphenyl) -piperazin-1-yl] -methanone in 30 ml of pyridine was added to T = -10 ° C cooled and reacted at this temperature with 0.72 g (2.68 mmol) of diphenylchlorophosphate and 0.58 g (4.5 mmol) of diisopropylethylamine for 1.5 hours to react. The mixture was then diluted with 10 ml of dichloromethane and extracted three times with 10 ml of water. The solvent of the organic phase was distilled i. Vak. Purified the residue on a silica gel column (Kieselgel 60, Fa. Merck AG, Darmstadt) using the eluent dichloromethane / methanol (97: 3 v / v).
Yield: 134 mg (13.3% of theory)
1 H-NMR (DMSO-d 6 ) δ = 8.25 (d, 1H), 8.06-8.0 (m, 3H), 7.78 (m, 2H), 7.46-7.23 (m, 22H), 7.1 (t, 1H) , 6.42 (m, 1H), 3.7-3.1 (m, 11H) ppm.
31 P-NMR (DMSO-d6): δ = -18.2, -17.8 ppm
Beispiel 9 (Umsetzung gemäß Schema 3):Example 9 (Reaction according to the scheme 3):
Essigsäure-3-acetoxy-9-[4-(3-methoxy-phenyl)-piperazin-1-carbonyl]-acridin-1-yl-ester (18)Acetic acid 3-acetoxy-9- [4- (3-methoxy-phenyl) -piperazine-1-carbonyl] -acridin-1-yl-ester (18)
Eine
Lösung
von 0.30 g (0.7 mMol) (1,3-Dihydroxy-acridin-9-yl)-[4-(3-methoxyphenyl)-piperazin-1yl]-methanon
in 20 ml Dimethylformamid wurde 30 Minuten mit 0.18 g (1.75 mMol)
Triethylamin und anschliessend mit 0.11 g (1.4 mMol) Essigsäureanhydrid
0.75 Stunden zur Reaktion gebracht. Anschliessend verdünnte man
den Ansatz mit 10 m1 Dichlormethan und extrahierte dreimal mit jeweils
10 ml Wasser. Das Lösungsmittel
der organischen Phase destillierte man i. Vak. ab und reinigte den
Rückstand über eine
Kieselgelsäule
(Kieselgel 60, Fa. Merck AG, Darmstadt) unter Anwendung des Elutionsmittels
Dichlormethan/Methanol (97:3 V/V).
Ausbeute: 308 mg (81.5%
d. Th.)
1H-NMR (DMSO-d6) δ = 8.24 (d,
1H), 8.0-7.9 (m, 3H), 7.72 (t, 1H), 7.12 (t, 1H), 6.53-6.38 (m, 4H), 4.35
(m, 1-H), 3.84 (m, 1H), 3.73 (m, 4H), 3.56 (m, 1H), 3.08-2.96 (m,
3H), 2.74 (m, 1H), 2.38, 2.36 (2s, 6H) ppm.A solution of 0.30 g (0.7 mmol) of (1,3-dihydroxy-acridin-9-yl) - [4- (3-methoxyphenyl) -piperazin-1-yl] -methanone in 20 ml of dimethylformamide was added 0.18 g (1.75 g) for 30 minutes mmol) triethylamine and then reacted with 0.11 g (1.4 mmol) of acetic anhydride for 0.75 hours. The mixture was then diluted with 10 ml of dichloromethane and extracted three times with 10 ml of water. The solvent of the organic phase was distilled i. Vak. Purified the residue on a silica gel column (Kieselgel 60, Fa. Merck AG, Darmstadt) using the eluent dichloromethane / methanol (97: 3 v / v).
Yield: 308 mg (81.5% of theory)
1 H-NMR (DMSO-d 6) δ = 8.24 (d, 1H), 8.0-7.9 (m, 3H), 7.72 (t, 1H), 7.12 (t, 1H), 6:53 to 6:38 (m, 4H) , 4.35 (m, 1-H), 3.84 (m, 1H), 3.73 (m, 4H), 3.56 (m, 1H), 3.08-2.96 (m, 3H), 2.74 (m, 1H), 2.38, 2.36 (2s, 6H) ppm.
Folgende Verbindungen der allgemeinen Formel 1 wurden analog zum Syntheseweg in Schema 1, 2 und 3 synthetisiert: The following compounds of the general formula 1 were synthesized analogously to the synthesis route in Schemes 1, 2 and 3:
Beispiel 10:Example 10:
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester-2-chlorethylester (6)Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester 2-chloroethyl ester (6)
- Fp.: 162–163°C.Mp: 162-163 ° C.
- 1H-NMR (DMSO-d6) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.25 (dd, 1H), 6.85 (dd, 1H), 6.81 (s, 1H), 6.66 (dd, 1H), 4.42-4.45 (m, 2H), 4.10-4.12 (m, 2H), 3.89-3.92 (m, 2H), 3.49-3.53 (m, 2H), 3.10-3.13 (m, 2H), 2.98-3.00 (m, 2H) ppm. 1 H-NMR (DMSO-d 6) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.25 (dd, 1H), 6.85 (dd , 1H), 6.81 (s, 1H), 6.66 (dd, 1H), 4.42-4.45 (m, 2H), 4.10-4.12 (m, 2H), 3.89-3.92 (m, 2H), 3.49-3.53 (m , 2H), 3.10-3.13 (m, 2H), 2.98-3.00 (m, 2H) ppm.
Beispiel 11:Example 11:
(2-Hydroxy-ethyl)-carbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester (7)(2-Hydroxyethyl) -carbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (7)
- Fp.: ab 116°C Zersetzung.Fp .: from 116 ° C Decomposition.
- 1H-NMR (DMSO-d6) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.61 (t, 1H),7.18 (dd, 1H), 6.76 (dd, 1H), 6.62 (s, 1H), 6.52 (dd, 1H), 4.69 (t, 1H), 4.10-4.12 (m, 2H), 3.41-3.49 (m, 4H), 3.07-3.13 (m, 4H), 2.94-2.97 (m, 2H) ppm. 1 H-NMR (DMSO-d 6 ) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.61 (t, 1H), 7.18 (dd , 1H), 6.76 (dd, 1H), 6.62 (s, 1H), 6.52 (dd, 1H), 4.69 (t, 1H), 4.10-4.12 (m, 2H), 3.41-3.49 (m, 4H), 3.07-3.13 (m, 4H), 2.94-2.97 (m, 2H) ppm.
Beispiel 12:Example 12:
[4-(3-Chlorphenyl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon (8)[4- (3-chlorophenyl) piperazin-1-yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (8th)
- 1H-NMR (DMSO-d6) δ = 10.95 (s, 1H), 10.3 (s, 1H), 7.94 (d, 1H), 7.83 (d, 1H), 7.76 (t, 1H), 7.48 (t, 1H), 7.23 (t, 1H), 6.96 (m, 1H), 6.9 (m, 1H), 6.86 (s, 1H), 6.82 (m, 1H), 6.55 (s, 1H), 4.1 (m, 1H), 3.77 (m, 1H), 3.5 (m, 1H), 3.22 (m, 1H), 3.07 (m, 2H), 3.15 (m, 1H), 2.86 (m, 1H) ppm. 1 H-NMR (DMSO-d 6) δ = 10.95 (s, 1H), 10.3 (s, 1H), 7.94 (d, 1H), 7.83 (d, 1H), 7.76 (t, 1H), 7:48 (t , 1H), 7.23 (t, 1H), 6.96 (m, 1H), 6.9 (m, 1H), 6.86 (s, 1H), 6.82 (m, 1H), 6.55 (s, 1H), 4.1 (m, 1H), 3.77 (m, 1H), 3.5 (m, 1H), 3.22 (m, 1H), 3.07 (m, 2H), 3.15 (m, 1H), 2.86 (m, 1H) ppm.
Beispiel 13:Example 13:
[4-(6-Chlorpyridin-2yl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon (9)[4- (6-chloropyridin-2-yl) piperazin-1-yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (9)
- 1H-NMR (DMSO-d6) δ = 10.9 (s, 1H), 10.3 (s, 1H), 7.96 (d, 1H), 7.83 (d, 1H), 7.76 (t, 1H), 7.57 (t, 1H), 7.47 (t, 1H), 6.87 (m, 1H), 6.79 (d, 1H), 6.7 (d, 1H), 4.06 (m, 1H), 3.84 (m, 1H), 3.65-3.78 (m, 2H), 3.53 (m, 1H), 3.2 (m, 1H), 3.05 (m, 2H) ppm. 1 H-NMR (DMSO-d 6) δ = 10.9 (s, 1H), 10.3 (s, 1H), 7.96 (d, 1H), 7.83 (d, 1H), 7.76 (t, 1H), 7:57 (t , 1H), 7.47 (t, 1H), 6.87 (m, 1H), 6.79 (d, 1H), 6.7 (d, 1H), 4.06 (m, 1H), 3.84 (m, 1H), 3.65-3.78 ( m, 2H), 3.53 (m, 1H), 3.2 (m, 1H), 3.05 (m, 2H) ppm.
Beispiel 14:Example 14:
(1,3-Dihydroxy-acridin-9-yl)-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4yl)-methanon (10)(1,3-dihydroxy-acridin-9-yl) - (2,3,5,6-tetrahydro- [1,2 '] bipyrazinyl-4-yl) -methanone (10)
- 1H-NMR (DMSO-d6) δ = 10.95 (s, 1H), 10.3 (s, 1H), 8.3 (s, 1H), 8.1 (s, 1H), 7.96 (d, 1H), 7.87 (d, 1H), 7.83 (d, 1H) 7.75 (t, 1H), 7.47 (t, 1H), 6.87 (m, 1H), 6.53 (m, 1H), 4.05 (m, 1H), 3.85 (m, 1H), 3.73 (m, 2H), 3.62 (m, 1H), 3.1 (m, 2H) ppm. 1 H-NMR (DMSO-d 6) δ = 10.95 (s, 1H), 10.3 (s, 1H), 8.3 (s, 1H), 8.1 (s, 1H), 7.96 (d, 1H), 7.87 (d , 1H), 7.83 (d, 1H) 7.75 (t, 1H), 7.47 (t, 1H), 6.87 (m, 1H), 6.53 (m, 1H), 4.05 (m, 1H), 3.85 (m, 1H ), 3.73 (m, 2H), 3.62 (m, 1H), 3.1 (m, 2H) ppm.
Beispiel 15:Example 15:
Phosphorsäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester (11)Phosphorsäurebis- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester (11)
- M: 828 g/mol; gefundene Molmasse 829.2 [M + H]+ M: 828 g / mol; molecular weight found 829.2 [M + H] +
- 1H-NMR (DMSO-d6): δ = 8.26 (d, 4H), 8.00 (d, 4H), 7.98 (t, 4H), 7.74 (t, 4H), 7.13 (t, 2H), 6.67-6.62 (m, 6H), 4.07-4.05 (m, 4H), 3.41-3.39 (m, 4H), 3.09-3.07 (m, 4H), 2.87-2.85 (m, 4H). 1 H-NMR (DMSO-d 6 ): δ = 8.26 (d, 4H), 8.00 (d, 4H), 7.98 (t, 4H), 7.74 (t, 4H), 7.13 (t, 2H), 6.67- 6.62 (m, 6H), 4.07-4.05 (m, 4H), 3.41-3.39 (m, 4H), 3.09-3.07 (m, 4H), 2.87-2.85 (m, 4H).
- 31P-NMR DMSO-d6): δ = –12.18ppm 31 P-NMR DMSO-d6): δ = -12.18 ppm
Beispiel 16:Example 16:
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methoxy-pyridin-2yl)-piperazin-1yl]-methanon (12)(1,3-dihydroxy-acridin-9-yl) - [4- (6-methoxy-pyridin-2-yl) piperazin-1-yl] -methanone (12)
- 1H-NMR (DMSO-d6) δ = 10.9 (s, 1H), 10.3 (s, 1H), 7.96 (d, 1H), 7.82 (d, 1H), 7.75 (t, 1H), 7.45 (m, 2H), 6.86 (s, 1H), 6.33 (d, 1H), 6.07 (d, 1H), 4.05 (m, 1H), 3.84 (m, 1H), 3.73 (m, 4H), 3.64 (m, 1H), 3.54 (m, 1H), 3.05 (m, 2H) ppm. 1 H-NMR (DMSO-d 6) δ = 10.9 (s, 1H), 10.3 (s, 1H), 7.96 (d, 1H), 7.82 (d, 1H), 7.75 (t, 1H), 7:45 (m , 2H), 6.86 (s, 1H), 6.33 (d, 1H), 6.07 (d, 1H), 4.05 (m, 1H), 3.84 (m, 1H), 3.73 (m, 4H), 3.64 (m, 1H), 3.54 (m, 1H), 3.05 (m, 2H) ppm.
Beispiel 17:Example 17:
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanon (13)(1,3-dihydroxy-acridin-9-yl) - [4- (3-hydroxyphenyl) piperazin-1-yl] -methanone (13)
- 1H-NMR (DMSO-d6) δ = 10.9 (s, 1H), 10.3 (s, 1H), 9.16 (s, 1H), 7.96 (m, 1H), 7.8 (t, 1H), 7.75 (t, 1H), 7.46 (t, 1H), 6.96 (t, 1H), 6.85 (m, 1H), 6.56 (m, 1H), 6.36 (m, 1H), 6.3 (m, 1H), 6.23 (m, 1H), 4.1 (m, 1H), 3.75 (m, 1H), 3.42 (m, 1H), 3.22 (m, 1H), 2.9 (m, 1H), 2.76 (m, 1H), 2.27 (m, 1H) ppm. 1 H-NMR (DMSO-d 6 ) δ = 10.9 (s, 1H), 10.3 (s, 1H), 9.16 (s, 1H), 7.96 (m, 1H), 7.8 (t, 1H), 7.75 (t , 1H), 7.46 (t, 1H), 6.96 (t, 1H), 6.85 (m, 1H), 6.56 (m, 1H), 6.36 (m, 1H), 6.3 (m, 1H), 6.23 (m, 1H), 4.1 (m, 1H), 3.75 (m, 1H), 3.42 (m, 1H), 3.22 (m, 1H), 2.9 (m, 1H), 2.76 (m, 1H), 2.27 (m, 1H ) ppm.
Beispiel 18:Example 18:
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-methoxyphenyl)-piperazin-1yl]-methanon (14)(1,3-dihydroxy-acridin-9-yl) - [4- (3-methoxyphenyl) piperazin-1-yl] -methanone (14)
- 1H-NMR (DMSO-d6) δ = 10.95 (s, 1H), 10.3 (s, 1H), 7.97 (m, 2H), 7.82 (m, 1H), 7.75 (t, 1H), 7.47 (t, 1H), 7.1 (t, 1H), 6.53 (m, 2H), 6.45 (m, 1H), 6.38 (m, 1H), 4.1 (m, 1H), 3.68-3.78 (m, 5H), 3.47 (m, 1H), 3.15 (m, 1H), 3.05 (m, 1H), 2.84 (m, 1H) ppm. 1 H-NMR (DMSO-d 6) δ = 10.95 (s, 1H), 10.3 (s, 1H), 7.97 (m, 2H), 7.82 (m, 1H), 7.75 (t, 1H), 7:47 (t , 1H), 7.1 (t, 1H), 6.53 (m, 2H), 6.45 (m, 1H), 6.38 (m, 1H), 4.1 (m, 1H), 3.68-3.78 (m, 5H), 3.47 ( m, 1H), 3.15 (m, 1H), 3.05 (m, 1H), 2.84 (m, 1H) ppm.
Beispiel 19:Example 19:
Kohlensäure-3-[4-(acridin-9-carbonyl)piperazin-1-yl]phenylester-2,2-dimethyl-[1,3]dioxolan-4-ylmethylester (16)Carbonic acid 3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl ester 2,2-dimethyl- [1,3] dioxolan-4-ylmethyl ester (16)
- Fp.: 107–108°C.Mp .: 107-108 ° C.
- 1H-NMR (DMSO-d6) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.24 (dd, 1H), 6.84 (dd, 1H), 6.79 (s, 1H), 6.55 (dd, 1H), 4.31-4,36 (m, 1H), 4.27 (dd, 1H), 4.14 (dd, 1H), 4.10-4.12 (m, 2H), 3.73 (dd, 1H), 3.10-3.13 (m, 2H), 2.97-2.30 (m, 2H), 1.34 (s, 3H), 1.28 (s, 3H) ppm. 1 H-NMR (DMSO-d 6 ) δ = 8.24 (d, 2H), 7.99 (d, 2H), 7.92 (dd, 2H), 7.71 (dd, 2H), 7.24 (dd, 1H), 6.84 (dd , 1H), 6.79 (s, 1H), 6.55 (dd, 1H), 4.31-4.36 (m, 1H), 4.27 (dd, 1H), 4.14 (dd, 1H), 4.10-4.12 (m, 2H ), 3.73 (dd, 1H), 3.10-3.13 (m, 2H), 2.97-2.30 (m, 2H), 1.34 (s, 3H), 1.28 (s, 3H) ppm.
Beispiel 20:Example 20:
Kohlensäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester (19)Kohlensäurebis- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester (19)
- ESIMS: 793.2 [M + H]+, 397.2 [M + 2H]++.ESIMS: 793.2 [M + H] + , 397.2 [M + 2H] ++ .
- 1H-NMR (DMSO-d6) δ = 8.24 (d, 4H), 7.99 (d, 4H), 7.92 (dd, 4H), 7.70 (dd, 4H), 7.27 (dd, 2H), 6.90 (s, 2H), 6.87 (dd, 2H), 6.74 (dd, 2H), 4.10-4.13 (m, 4H), 3.50-3.53 (m, 4H), 3.11-3.13 (m, 4H), 2.98-3.01 (m, 4H) ppm. 1 H-NMR (DMSO-d 6) δ = 8.24 (d, 4H), 7.99 (d, 4H), 7.92 (dd, 4H), 7.70 (dd, 4H), 7.27 (dd, 2H), 6.90 (s , 2H), 6.87 (dd, 2H), 6.74 (dd, 2H), 4.10-4.13 (m, 4H), 3.50-3.53 (m, 4H), 3.11-3.13 (m, 4H), 2.98-3.01 (m , 4H) ppm.
Die
am meisten bevorzugten Verbindungen der vorliegenden Erfindung sind
Substanzen der allgemeinen Formel 1 in Form ihrer Basen oder ihrer
pharmazeutisch annehmbaren Salze, die aus der folgenden Gruppe ausgewählt sind:
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methyl-pyridin-2yl)-piperazin-1yl]-methanon
(1)
Isopropylcarbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(2)
Essigsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(3)
Phosphorsäure
mono-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester (4)
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylestermethylester
(5)
Kohlensäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester-2-chlorethylester
(6)
(2-Hydroxy-ethyl)-carbaminsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(7)
[4-(3-Chlorphenyl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon
(8)
[4-(6-Chlorpyridin-2yl)-piperazin-1yl]-(1,3-dihydroxy-acridin-9-yl)-methanon
(9)
(1,3-Dihydroxy-acridin-9-yl)-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4yl)-methanon
(10)
Phosphorsäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester
(11)
(1,3-Dihydroxy-acridin-9-yl)-[4-(6-methoxy-pyridin-2yl)-piperazin-1yl]-methanon
(12)
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-hydroxyphenyl)-piperazin-1yl]-methanon
(13)
(1,3-Dihydroxy-acridin-9-yl)-[4-(3-methoxyphenyl)-piperazin-1yl]-methanon
(14)
Methansulfonsäure-3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenylester
(15)
Kohlensäure-3-[4-(acridin-9-carbonyl)piperazin-1-yl]phenylester-2,2-dimethyl[1,3]dioxolan-4-ylmethylester (16)
Phosphorsäure-3-(diphenoxy-phosphoryloxy)-9-[4-(3-methoxyphenyl)-piperazin-1-carbonyl]-acridin-1-yl-esterdiphenylester
(17)
Essigsäure-3-acetoxy-9-[4-(3-methoxy-phenyl)-piperazin-1-carbonyl]-acridin-1-yl-ester (18)
Kohlensäurebis-{3-[4-(acridin-9-carbonyl)-piperazin-1-yl]-phenyl}ester
(19)The most preferred compounds of the present invention are substances of general formula 1 in the form of their bases or their pharmaceutically acceptable salts, selected from the following group:
(1,3-Dihydroxy-acridin-9-yl) - [4- (6-methyl-pyridin-2yl) -piperazin-1-yl] -methanone (1)
Isopropylcarbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (2)
Acetic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (3)
Phosphoric acid mono- {3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl} ester (4)
Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester methyl ester (5)
Carbonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester 2-chloroethyl ester (6)
(2-Hydroxyethyl) -carbamic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (7)
[4- (3-Chlorophenyl) piperazin-1yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (8)
[4- (6-chloropyridin-2yl) -piperazin-1yl] - (1,3-dihydroxy-acridin-9-yl) -methanone (9)
(1,3-Dihydroxy-acridin-9-yl) - (2,3,5,6-tetrahydro- [1,2 '] bipyrazinyl-4-yl) -methanone (10)
Phosphoric acid bis {3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl} ester (11)
(1,3-Dihydroxy-acridin-9-yl) - [4- (6-methoxy-pyridin-2-yl) -piperazin-1-yl] -methanone (12)
(1,3-Dihydroxy-acridin-9-yl) - [4- (3-hydroxyphenyl) -piperazin-1-yl] -methanone (13)
(1,3-Dihydroxy-acridin-9-yl) - [4- (3-methoxyphenyl) -piperazin-1-yl] -methanone (14)
Methanesulfonic acid 3- [4- (acridine-9-carbonyl) -piperazin-1-yl] -phenyl ester (15)
Carbonic acid 3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl ester 2,2-dimethyl [1,3] dioxolan-4-ylmethyl ester (16)
Phosphoric acid 3- (diphenoxy-phosphoryloxy) -9- [4- (3-methoxyphenyl) -piperazine-1-carbonyl] -acridin-1-yl-esterdiphenyl ester (17)
Acetic acid 3-acetoxy-9- [4- (3-methoxy-phenyl) -piperazine-1-carbonyl] -acridin-1-yl-ester (18)
Carbonic acid bis {3- [4- (acridine-9-carbonyl) piperazin-1-yl] phenyl} ester (19)
Biologische Wirkungen der erfindungsgemäßen VerbindungenBiological effects the compounds of the invention
Die in-vitro Testung an ausgewählten Tumormodellen ergab die nachfolgenden pharmakologischen Aktivitäten.The in vitro testing on selected Tumor models revealed the following pharmacological activities.
Beispiel 21: Antiproliferative Wirkung an verschiedenen TumorzellinienExample 21: Antiproliferative Effect on different tumor cell lines
Die erfindungsgemäßen Verbindungen wurden in einem Proliferationstest an etablierten Tumorzellinien auf ihre anti-proliferative Aktivität hin untersucht. Der verwendete Test bestimmt die zelluläre Dehydrogenase-Aktivität und ermöglicht eine Bestimmung der Zellvitalität und indirekt der Zellzahl. Bei den verwendeten Zellinien handelt es sich um die humane Cervixkarzinom Zellinie KB/HeLa (ATCC CCL17), die ovariale Adeno-karzinomzellinie SKOV-3 (ATCC HTB77), die humane Glioblastom Zellinie SF-268 (NCI 503138) und die Lungenkarzinom Zellinie NCI-N460 (NCI 503473). Die Ergebnisse zeigen eine sehr potente Hemmung der Proliferation ausgewählter Tumorzelllinien durch die erfindungsgemäßen Verbindungen.The Compounds of the invention were in a proliferation test on established tumor cell lines tested for their anti-proliferative activity. The used Test determines the cellular Dehydrogenase activity and allows a determination of cell vitality and indirectly the cell number. The cell lines used are it is the human cervical carcinoma cell line KB / HeLa (ATCC CCL17), the ovarian adenocarcinoma cell line SKOV-3 (ATCC HTB77), the human Glioblastoma cell line SF-268 (NCI 503138) and lung carcinoma Cell line NCI-N460 (NCI 503473). The results show a lot potent inhibition of the proliferation of selected tumor cell lines the compounds of the invention.
Tabelle 1: Proliferationshemmung der erfindungsgemäßen Verbindungen im XTT Zytotoxizitätstest an humanen Tumorzellinien Table 1: Proliferation inhibition of the compounds according to the invention in the XTT cytotoxicity test on human tumor cell lines
Beispiel 22: Inhibierung der Polymerisation von TubulinExample 22: Inhibition the polymerization of tubulin
Die erfindungsgemäßen Verbindungen wurden in einem in-vitro Test auf Hemmung der Polymerisation von Rindertubulin getestet. In diesem Test wird in Zyklen von Polymerisation und Depolymerisation aufgereinigtes Tubulin eingesetzt, welches durch Zugabe von GTP und Erwärmung zur Polymerisation gebracht wird. In Tabelle 2 sind die Inhibierungs- bzw. EC50-Werte der Polymerisationshemmung von Tubulin mit 30% assoziierten Proteinen (MAPs) angegeben. Die Ergebnisse zeigen eine sehr potente Hemmwirkung der erfindungsgemäßen Verbindungen auf die Polymerisation von Tubulin.The Compounds of the invention were used in an in vitro test for inhibition of the polymerization of Bovine tubulin tested. This test is used in cycles of polymerization and Depolymerisation purified tubulin used, which by adding GTP and heating is brought to the polymerization. Table 2 shows the inhibition or EC50 values of the polymerization inhibition of tubulin associated with 30% Proteins (MAPs) indicated. The results show a very potent Inhibitory effect of the compounds of the invention on the polymerization of tubulin.
Tabelle 2: Hemmung der Tubulin-Polymerisation. Durchschnittswert aus zwei unabhängigen Versuchen. (n.b.: nicht bestimmt) Table 2: Inhibition of tubulin polymerization. Average of two independent experiments. (nb: not determined)
Beschreibung der verwendeten Methoden XTT-Test auf zelluläre Dehydrogenase-Aktivitätdescription The methods used XTT test for cellular dehydrogenase activity
Die adherent wachsenden Tumorzellinien KB/HeLa, SKOV-3, SF-268, NCI-H460, ASPC1, A172, A431, A549, DU145, C6, MDAMB435, HT29, PC3, T47D, U118MG und U373MG wurden unter Standardbedingungen im Begasungsbrutschrank bei 37°C, 5% CO2 und 95% Luftfeuchtigkeit kultiviert. Am Versuchstag 1 werden die Zellen mit Trypsin/EDTA abgelöst und durch Zentrifugation pelletiert. Nachfolgend wird das Zellpellet in dem jeweiligen Kulturmedium in der entsprechenden Zellzahl resuspendiert und in eine 96-well Mikrotiterplatte umgesetzt. Die Platten werden dann über Nacht im Begasungsbrutschrank kultiviert. Die Testsubstanzen werden als 1 mg/ml Stammlösungen in DMSO angesetzt und am Versuchstag 2 mit Kulturmedium in den entsprechenden Konzentrationen verdünnt. Die Substanzen in Kulturmedium werden dann zu den Zellen gegeben und für 45h im Begasungsbrutschrank inkubiert. Als Kontrolle dienen Zellen, die nicht mit Testsubstanz behandelt werden. Für das XTT-Assay werden 1 mg/ml XTT (Natrium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzensulfonsäure) in RPMI-1640 Medium ohne Phenolrot gelöst. Zusätzlich wird eine 0,383 mg/ml PMS (N-Methyl Dibenzopyrazine Methylsulfat) Lösung in Phosphat-gepufferter Salzlösung (PBS) hergestellt. Am Versuchstag 4 wird auf die Zellplatten, die inzwischen 45 h mit den Testsubstanzen inkubiert wurden, 75 μl/well XTT-PMS-Mischung pipettiert. Dazu wird kurz vor Gebrauch die XTT-Lösung mit der PMS-Lösung im Verhältnis 50:1 (Vol:Vol) gemischt. Anschließend werden die Zellplatten im Begasungsbrutschrank für weitere 3h inkubiert und im Photometer die optische Dichte (OD490nm) bestimmt. Mittels der bestimmten OD490nm, wird die prozentuale Hemmung relativ zur Kontrolle berechnet und in Form einer Konzentrations-Wirkungskurve halblogarithmisch aufgetragen. Die EC50 wird mittels einer Regressionsanalyse aus der Konzentrations-Wirkungskurve mit dem Programm Graphpad Prism berechnet.The adherently growing tumor cell lines KB / HeLa, SKOV-3, SF-268, NCI-H460, ASPC1, A172, A431, A549, DU145, C6, MDAMB435, HT29, PC3, T47D, U118MG and U373MG were incubated under standard conditions in the fumigation incubator at 37 ° C, 5% CO 2 and 95% humidity. On day 1 of the experiment the cells are detached with trypsin / EDTA and pelleted by centrifugation. Subsequently, the cell pellet is resuspended in the respective culture medium in the appropriate cell number and converted into a 96-well microtiter plate. The plates are then cultivated overnight in the fumigation incubator. The test substances are prepared as 1 mg / ml stock solutions in DMSO and diluted on test day 2 with culture medium in the appropriate concentrations. The substances in culture medium are then added to the cells and incubated for 45 hours in the fumigation incubator. The control cells are those that are not treated with test substance. For the XTT assay, 1 mg / ml XTT (sodium 3 '- [1- (phenylaminocarbonyl) -3,4-tetrazolium] -bis (4-methoxy-6-nitro) benzenesulfonic acid) is dissolved in RPMI-1640 medium without phenol red , Additionally, a 0.383 mg / ml PMS (N-methyl dibenzopyrazine methylsulfate) solution in phosphate buffered saline (PBS) is prepared. On test day 4, 75 μl / well XTT-PMS mixture is pipetted onto the cell plates which have been incubated with the test substances for 45 h. For this purpose, shortly before use, the XTT solution is mixed with the PMS solution in a ratio of 50: 1 (vol: vol). Subsequently, the cell plates are incubated in the fumigation incubator for a further 3 h and the optical density (OD 490 nm ) is determined in the photometer. By means of the determined OD 490nm , the percentage inhibition is calculated relative to the control and plotted semilogarithmically in the form of a concentration-effect curve. The EC 50 is calculated by means of a regression analysis from the concentration-effect curve with the program Graphpad Prism.
Tubulin Polymerisations AssayTubulin polymerization assay
Das Assay wird basierend auf der Methode von Bollag et. al. durchgeführt. Lyophylisiertes Rindertubulin (Cytoskeleton, ML 113 Tubulin 30% MAPs) wird in einer Konzentration von 2 mg/ml (ML113 in 80 mM PIPES, 0.5 mM EGTA, 2 mM MgC12, pH6.9, 1 mM GTP). bzw 5 mg/ml (TL238 in 80 mM PIPES, 1 mM EGTA, 0.5 mM MgCl2, 20% (v:v) Glycerol pH6.9, 1 mM GTP) gelöst. Die Testsubstanzen werden in 10% DMSO (v:v) verdünnt und 5 μl der Verdünnungen auf eine 96-Well Mikrotiterplatte (Nunc, half area plate) transferiert. Nach Zugabe von 45 μl der Tubulinlösung wird die Polymerisation bei 340 nm in einem Spectramax 190 Mikrotiterplattenreader (Molecular devices) mittels Kinetik Programm in 30 sec Intervallen über einen Zeitraum von 20 min bestimmt. Die resultierenden area under curve Werte werden zur Berechnung der Inhibition in Bezug auf die unbehandelte Kontrolle verwendet. Die Kontrollen sind unbehandelte Zellen (+/– Induktion). Die Induktion erfolgt mit 3 μM Muristeron A. Am 1. Tag werden die Zellen ausgesetzt (+/– Muristeron A) und für 24h bei 37°C inkubiert. Am Tag 2 wird die Testsubstanz zugegeben (Kontrolle DMSO) und für weitere 45h bei 37°C inkubiert, bevor ein Standard XTT-Assay durchgeführt wird.The assay is based on the method of Bollag et. al. carried out. Lyophilized bovine tubulin (cytoskeleton, ML 113 tubulin 30% MAPs) is added at a concentration of 2 mg / ml (ML113 in 80 mM PIPES, 0.5 mM EGTA, 2 mM MgCl 2 , pH 6.9, 1 mM GTP). or 5 mg / ml (TL238 in 80 mM PIPES, 1 mM EGTA, 0.5 mM MgCl 2 , 20% (v: v) glycerol pH6.9, 1 mM GTP). The test substances are diluted in 10% DMSO (v: v) and 5 μl of the dilutions are transferred to a 96-well microtiter plate (Nunc, half area plate). After addition of 45 μl of the tubulin solution, the polymerization is determined at 340 nm in a Spectramax 190 microtiter plate reader (Molecular Devices) by means of a kinetics program at 30 sec intervals over a period of 20 min. The resulting area under curve values are used to calculate the inhibition relative to the untreated control. The controls are untreated cells (+/- induction). The induction is carried out with 3 μM muristerone A. On the first day the cells are exposed (+/- Muristeron A) and incubated for 24 h at 37 ° C. On day 2, the test substance is added (control DMSO) and incubated for a further 45h at 37 ° C before a standard XTT assay is performed.
Beispiel 23: Sättigungslöslichkeit in WasserExample 23: Saturation solubility in water
Die Bestimmung der Sättigungslöslichkeit in Wasser erfolgte wie nachfolgend beschrieben. Zum Anlösen der Substanzen und um die Benetzung der Proben zu verbessern wurde maximal 1% DMSO zugesetzt. Zur Überprüfung des Gehaltes wurde eine HPLC-UV-Methode angewandt. Die Ergebnisse sind in der nachfolgenden Tabelle zusammengefasst.The determination of the saturation solubility in water was carried out as described below. To dissolve the substances and to improve the wetting of the samples, a maximum of 1% DMSO was added. To check the content, an HPLC-UV method was used. The results are summarized in the table below.
Beispiele für pharmazeutische DarreichungsformenExamples for pharmaceutical dosage forms
Beispiel IExample I
Tablette mit 50 mg WirkstoffTablet with 50 mg active ingredient
Zusammensetzung:
Herstellung:production:
(1), (2) und (3) werden gemischt und mit einer wäßrigen Lösung von (4) granuliert.(1), (2) and (3) are mixed and granulated with an aqueous solution of (4).
Dem getrockneten Granulat wird (5) zugemischt. Aus dieser Mischung werden Tabletten gepreßt.the dried granules are mixed (5). Become from this mix Pressed tablets.
Beispiel IIExample II
Kapsel mit 50 mg WirkstoffCapsule with 50 mg active ingredient
Zusammensetzung:
Herstellung:production:
(1) wird mit (3) verrieben. Diese Verreibung wird der Mischung aus (2) und (4) unter intensiver Mischung zugegeben. Diese Pulvermischung wird auf einer Kapselabfüllmaschine in Hartgelatine-Steckkapseln Größe 3 abgefüllt.(1) is triturated with (3). This trituration becomes the mixture of (2) and (4) added with intensive mixing. This powder mixture is on a capsule filling machine filled into hard gelatine capsules size 3.
Claims (13)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10331500A DE10331500A1 (en) | 2003-07-11 | 2003-07-11 | Novel acridine derivatives and their use as pharmaceuticals |
PCT/EP2004/007020 WO2005007643A1 (en) | 2003-07-11 | 2004-06-29 | Novel acridine derivatives and use thereof as medicaments |
TW093119216A TW200504051A (en) | 2003-07-11 | 2004-06-29 | Novel acridine derivatives and their use as medicaments |
ARP040102438A AR045987A1 (en) | 2003-07-11 | 2004-07-08 | ACRIDINE DERIVATIVES, PROCEDURE TO PREPARE THEM AND THEIR USE TO PREPARE MEDICINES |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10331500A DE10331500A1 (en) | 2003-07-11 | 2003-07-11 | Novel acridine derivatives and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10331500A1 true DE10331500A1 (en) | 2005-02-24 |
Family
ID=34071629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10331500A Withdrawn DE10331500A1 (en) | 2003-07-11 | 2003-07-11 | Novel acridine derivatives and their use as pharmaceuticals |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR045987A1 (en) |
DE (1) | DE10331500A1 (en) |
TW (1) | TW200504051A (en) |
WO (1) | WO2005007643A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445686B2 (en) | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2831625T3 (en) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Therapeutic compounds and their uses |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
JP6426194B2 (en) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
BR112019004463A2 (en) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | crystalline forms of therapeutic compounds, their processes for obtaining and their methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10035927A1 (en) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | New heteroaryl derivatives and their use as medicines |
-
2003
- 2003-07-11 DE DE10331500A patent/DE10331500A1/en not_active Withdrawn
-
2004
- 2004-06-29 TW TW093119216A patent/TW200504051A/en unknown
- 2004-06-29 WO PCT/EP2004/007020 patent/WO2005007643A1/en active Application Filing
- 2004-07-08 AR ARP040102438A patent/AR045987A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005007643A1 (en) | 2005-01-27 |
TW200504051A (en) | 2005-02-01 |
AR045987A1 (en) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1636228B1 (en) | Novel pyridopyrazines and use thereof as kinase modulators | |
EP1280798B1 (en) | Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them | |
DE60022866T2 (en) | BICYCLIC HETEROCYCLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | |
EP1315718B1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
WO2004104002A1 (en) | Novel pyridopyrazines and use thereof as kinase inhibitors | |
WO2004002965A1 (en) | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases | |
DE102006050515A1 (en) | New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia | |
DE69818041T2 (en) | CYANOGUANIDINE AS A CELL PROLIFERATION INHIBITOR | |
DE102007061766A1 (en) | New 4-(4-cyano-2-thioaryl)-dihydro-pyrimidinone compounds are human neutrophil elastase inhibitor, useful for the treatment or prevention of e.g. pulmonary arterial hypertonia, acute lung injury and diseases of the cardiovascular system | |
EP2241557A1 (en) | Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses | |
CH637130A5 (en) | CHINAZOLINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE OF THESE DERIVATIVES IN MEDICINAL PRODUCTS. | |
DE10312969A1 (en) | Benzofuro-1,4-diazepin-2-one derivatives | |
DE10331500A1 (en) | Novel acridine derivatives and their use as pharmaceuticals | |
DE69817810T2 (en) | CYANOGUANIDINE AS A CELL PROLIFERATION INHIBITOR | |
DE60003045T2 (en) | HETEROCYCLIC COMPOUNDS AS ANGIOGENESIS INHIBITORS | |
EP1611126B1 (en) | Chromenone indoles | |
DE10042064A1 (en) | Chinazolines, medicaments containing these compounds, their use and processes for their preparation | |
US20050009809A1 (en) | Acridine derivatives and their use as medicaments | |
EP2755964A1 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
WO2004007470A1 (en) | Novel anthracene derivatives and the use thereof as a medicament | |
DE602004009097T2 (en) | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENAL DERIVATIVES | |
WO2005014542A2 (en) | Novel n-substituted indolyl-3-glyoxylic acid amides, use thereof as a medicament against cancer, and method for the production thereof | |
DE60203740T2 (en) | LUMINACINE ANALOGS AND ITS USE | |
EP1897864A1 (en) | Anthracene derivatives and the use thereof for treating benign and malignant tumors | |
DE10232525A1 (en) | New diazaheterocyclylcarbonyl-anthracene derivatives, useful as tubulin polymerization inhibitors for treating benign or malignant tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OR8 | Request for search as to paragraph 43 lit. 1 sentence 1 patent law | ||
8105 | Search report available | ||
8130 | Withdrawal |